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Tobacco use remains the Nation’s leading preventable cause of premature death. Each 
year, more than 440,000 Americans die from disease caused by tobacco use, accounting for one 
in every five deaths. Cigarette smoking alone is responsible for more than 30% of cancer deaths 
annually in the United States and smoking is also an important cause of death from heart disease, 
stroke, and chronic obstructive pulmonary disease. Currently, there are an estimated 44.5 million 
(21%) adult smokers and an estimated 3.75 million (22%) high school student smokers in the 
United States. Cigarettes are the predominant form of tobacco consumed; however, other forms 
of tobacco, such as smokeless tobacco, cigars, and pipes, are also used. In addition to the toll in 
human lives, tobacco use places an enormous economic burden on society. For 1995 to 1999, 
estimated annual smoking-attributable economic costs in the United States were $75.5 billion for 
direct medical care for adults and $81.9 billion for lost productivity.  
Despite enormous progress in reducing the prevalence of tobacco use in the United States, 
it is unlikely that the Healthy People 2010 objectives of reducing smoking prevalence to 12% or 
less in adults and 16% or less in youth will be reached on schedule. A better understanding of 
how effective strategies for prevention and treatment can be developed and implemented across 
diverse segments of the population is crucial to accelerate progress; meeting the Healthy People 
2010 prevalence goals is projected to prevent an additional 7.1 million premature deaths after 
2010. For this reason, the National Cancer Institute and the National Institutes of Health’s Office 
of Medical Applications of Research will sponsor a State-of-the-Science Conference on Tobacco 
Use: Prevention, Cessation, and Control, June 12–14, 2006, in Bethesda, Maryland. The key 
questions to be addressed at the State-of-the-Science Conference are:  
• What are the effective population- and community-based interventions to prevent 
tobacco use in adolescents and young adults, including among diverse populations? 
• What are the effective strategies for increasing consumer demand for and use of 
proven individually oriented cessation treatments, including among diverse 
populations?  
• What are the effective strategies for increasing the implementation of proven 
population-level tobacco-use cessation strategies, particularly by healthcare systems 
and communities?  
• What is the effect of smokeless tobacco product marketing and use on population 
harm from tobacco use?  
• What is the effectiveness of prevention and of cessation interventions in populations 
with co-occurring morbidities and risk behaviors?  
• What research is needed to make the most progress and greatest public health gains 
nationally and internationally?  
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At the conference, invited experts will present information pertinent to these questions, 
and a systematic literature review prepared under contract with the Agency for Healthcare 
Research and Quality (AHRQ) will be summarized. Conference attendees will have ample time 
to ask questions and provide statements during open discussion periods. After weighing the 
scientific evidence, an unbiased, independent panel will prepare and present a State-of-the-
Science statement addressing the key conference questions. This conference is intended for 
researchers interested in tobacco prevention, cessation, and control; healthcare professionals; 
healthcare system professionals; health policy experts; public health practitioners; and interested 
members of the public.  
General Information 
Conference sessions will be held in the Natcher Conference Center, NIH, Bethesda, 
Maryland. 
The conference may be viewed live via Webcast at http://videocast.nih.gov/. Webcast 
sessions will also be available after the conference. 
The dining center in the Natcher Conference Center is located on the main level, one 
floor above the auditorium. It is open from 6:30 a.m. to 2:30 p.m., serving hot breakfast and 
lunch, sandwiches and salads, and snack items. An additional cafeteria is available from 
7:00 a.m. to 3:30 p.m., in Building 38A, level B1, across the street from the main entrance to  
the Natcher Conference Center. 
The telephone number for the message center at the Natcher Conference Center is  
301–594–7302. 
Financial Disclosure 
Each speaker presenting at this conference has been asked to disclose any financial 
interests or other relationships pertaining to this subject area. Please refer to the material in your 
participant packet for details. 
Panel members signed a confirmation that they have no financial or other conflicts of 
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The following are the abstracts of the proposed speaker presentations at the NIH State-of-
the-Science Conference on Tobacco Use: Prevention, Cessation, and Control. They are designed 
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Background and Overview 
Gary A. Giovino, Ph.D., M.S. 
Introduction 
Tobacco use, primarily in the form of cigarettes, has caused more than 14 million 
premature deaths in the United States since 1964.1,2 Tobacco use remains the single leading 
preventable cause of death in the United States, with at least 8.6 million Americans living with 
serious disease(s) caused by their smoking, 400,000 current and former smokers dying annually 
from smoking-attributable diseases, and 38,000 nonsmokers dying annually because of exposure 
to tobacco smoke pollution.2–4 Peto and colleagues5 estimate that one-half of all smokers, 
especially those who began as teens, can expect to die of tobacco use. Of these, approximately 
one-half will die in middle age, losing on average 20–25 years of life expectancy. 
Overall U.S. consumption of tobacco products has been declining for several decades 
(figure 1). 6–8 From 1995 through 2004, consumption (in pounds) declined for cigarettes (by 
24%), smoking tobacco (i.e., pipe or roll-your-own) (by 23%), and chewing tobacco (by 64%); 
however, consumption increased for cigars (by 78%) and snuff (by 13%).8 The prevalence of 
cigarette smoking among U.S. adults has decreased substantially, from 42.4% in 1965 to 20.9% 
in 2004 (figure 2).9–11 Consumption of cigarettes has been increasing in developing nations, 
while decreasing in the United States and most high-income countries.12 
Figure 1. Trends in Per Capita Consumption of Various Tobacco Products—United 
States, 1880–2004 
Source:  U.S. Department of Agriculture; References 6–8.
Note: Among persons > 18 years old; Beginning in 1982, fine-cut chewing tobacco was reclassified as snuff. 






































































Figure 2. Trends in Cigarette Smoking* Among Adults Aged ≥18 Years, By Sex—
























Source: 1955 Current Population Survey; 1965–2004 National Health Interview Surveys; References 9–11.
*Before 1992, current smokers were defined as persons who reported having smoked >100 cigarettes and who currently 
smoked. Since 1992, current smokers were defined as persons who reported having smoked >100 cigarettes during their 




In 2004, the prevalence of cigarette smoking in the United States was higher for men 
(23.4%) than women (18.5%); for American Indians/Alaska Natives (33.4%) than for Hispanics 
(15.0%) and Asians (11.3%); for high school dropouts (34.0%) and those with a GED diploma 
(39.6%) than for those with an undergraduate (11.7%) or graduate (8.0%) degree; and for those 
living in poverty (29.1%) than for those living at or above the poverty line (20.6%).11 Among the 
estimated 42.4% (90.2 million) of persons who had ever smoked at least 100 lifetime cigarettes, 
50.6% (45.6 million) were former cigarette smokers.11 Among U.S. secondary school students, 
cigarette smoking prevalence increased markedly in the 1990s, peaking in 1996 for 8th and 10th 
graders and in 1997 for 12th graders (figure 3) and then subsequently declining.13 The 2005 data 
suggest that progress toward fewer student smokers is slowing and may even be stopping. 
Patterns of prevalence suggest that future tobacco-attributable disease will be increasingly 
concentrated in socially disadvantaged populations, further exacerbating health disparities. 
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Figure 3. Trends in Cigarette Smoking Anytime in the Past 30 days by Grade in 



























































Tobacco use is a multilevel problem that is influenced by a number of factors. An 
epidemiologic model of tobacco use and nicotine addiction (figure 4) highlights the importance 
of understanding the roles of the Agent (tobacco product), Host (smoker/user or potential 
smoker/user), Vector (tobacco product manufacturers), and Environment (e.g., familial, social, 
economic, and media factors).14–15  
Tobacco products have been changed substantially over the years to influence 
performance on standard machine tests and the bioavailability of nicotine.16–19 Light and ultra-
light cigarettes tacitly promise health benefits, but are as hazardous as full flavor varieties.1,17 
Cigarette companies have studied the smoothness of their products, in response to young 
smokers’ concerns about harsh taste.20,21 Research on traditional products and potential reduced-
exposure products (PREPs) is needed to determine likely human exposures to nicotine and 
toxic/carcinogenic compounds.22 In addition, the price of the product influences use, with 
increasing prices leading to decreased use, both by reducing the number of users and decreasing 
consumption among continuing users.23 
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The host is the person who uses the product. Some relevant host risk factors include 
biological susceptibility to addiction, in utero exposure to nicotine, motivation to start or quit, 
misperceptions, comorbidities, adverse childhood experiences, and self-esteem.24–27 This model 
also includes an incidental host, representing children and adults who are exposed to tobacco 
smoke pollution and are thus at increased risk of respiratory illnesses, lung cancer, coronary 
heart disease, and other diseases.28,29 
In epidemiology, the vector is the organism that transports the agent to susceptible 
individuals.30 Tobacco companies market their products to maximize appeal and allay health 
concerns.26,27,31,32 They undermine public health efforts by resisting the implementation of 
health-promoting programs and policies.33–37 They attempt to manipulate the work of scientists 
studying the health effects of their products.34,38–40 Companies have used pricing strategies, such 
as discount coupons and multipack discounts, to offset the effects of tax increases.41  
Environmental factors include familial, social, cultural, economic, historical, political, 
and media-based influences. For example, smoking by peers, siblings, and parents, as well as 
norms established in the home, can influence uptake.26,42 Tobacco growing and tobacco product 
manufacturing have in many countries become culturally established and economically powerful 
enterprises that greatly influence political decisions and even attitudes about use.34,36,37,43–45 
Other environmental factors include smoke-free air laws and policies, advice to quit from a 
health professional, and media influences, such as appearances of smoking in movies, 
pro-tobacco advertising and promotion, and anti-tobacco messages from the public health 
sector.15 The number of States passing smoke-free laws protecting all workers is increasing 
rapidly. As of April 2006, approximately 43% of U.S. adults live in an area where smoking is 
banned in private offices, restaurants, and/or bars.46 Still, many workers, especially those in the 
hospitality industry, remain unprotected.47 Laws protecting nonsmokers can also help smokers 
reduce consumption.48 In addition, substantial progress has been made in reducing children’s 
exposure in homes.49 
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Research activities and interventions can address one or more factors on the continuum 
from cells to society, all with the ultimate goal of minimizing tobacco use to the lowest level 
possible.50 
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Cultural Approaches to Community and School-Based 
Tobacco Prevention for Adolescents and Young Adults, 
Including Priority Populations 
Lourdes Baezconde-Garbanati, Ph.D., M.P.H. 
The United States has experienced a dramatic reduction in adolescent and adult smoking, 
with remarkable health benefits.1,2 However, among some groups—such as racial/ethnic 
minorities; those of low socioeconomic status (SES), especially youth; those 18–24 years of age; 
and lesbian, gay, bisexual, and transgender individuals (LGBT)—tobacco use remains a 
significant and persistent problem. It is also a major contributor to health disparities.3 
Role of Culture 
Although many multilevel factors contribute to adolescent and young adult smoking,4,5 
culture is one of the most powerful predictors of behavior and of the decision to smoke.5–9 
Considering the increased numbers of racial/ethnic and other cultural groups in the United States, 
communities are challenged in implementing evidence-based comprehensive tobacco prevention 
programs at the community and school levels and in proving their effectiveness. 
Community-Based Cultural Approaches 
California has been at the forefront in addressing diverse population tobacco prevention 
issues and in changing social and cultural norms that favor tobacco use in these communities.10 
Programs developed for these purposes are not necessarily youth focused, but are more 
community focused in their approach to preventing smoking and developing social norms. Yet 
they have been successful in helping to reduce the prevalence rate among youth and those 18–24 
years of age in part by changing social and cultural norms.3 To address the needs of particularly 
vulnerable populations at the community level, four ethnic networks/partnerships (African 
American [AA], American Indian [AI], Hispanic/Latino [H/L], and Asian/Pacific Islander [API]) 
were established in 1991 by the California Department of Health Services, Cancer Control 
Branch, Tobacco Control Section (TCS).10 Their purpose has been a common one: to address at a 
statewide level in culturally competent ways the technical assistance and training needs of TCS-
funded programs that focus on particularly vulnerable populations.  
The work has ranged from countering pro-tobacco influences on and targeting of the 
African American population with menthol cigarettes among the AA Tobacco Education 
Partnership to educating populations on the sacred use of tobacco by the AI Tobacco Education 
Partnership. The H/L Partnership has worked on smoke-free housing choice in various 
communities and inoculated Hispanic/Latino communities against industry sponsorship. The API 
Partnership has developed leadership strategies to move communities to readiness in tobacco 
control and focused on policies that promote Asian/Pacific Islander health. Since then, other 
programs have been established by the California TCS (the LGBT, low SES, and a program 
working with labor unions [BUILT]), forming a partnership with the ethnic networks known as 
California’s Priority Populations Partnerships.  
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As a group, the California Priority Population Partnerships have informed and educated 
policy- and decisionmakers on tobacco use and continued to address tobacco industry marketing 
with a special focus on those 18–24 years of age, secondhand smoke workplace policies that 
protect all Californians from the deleterious effects of tobacco smoke, and other issues in highly 
vulnerable populations or groups with particularly high prevalence rates.3 
Together with other competitive grantees, 68 Local Lead Agencies, a statewide and 
ethnic-specific media campaign, and a cadre of statewide programs, these efforts have formed 
part of the State of California’s comprehensive tobacco-control movement.3,10 They have built 
local and statewide tobacco control capacity at the community level, increased cultural 
competence among those conducting prevention and cessation efforts, created cultural specific 
and language appropriate approaches by partnering with tribal and local governments, advocacy 
and community groups, schools and college campuses. They have worked with the ethnic and 
general media promoting social change, bringing ethnic communities to the table, and 
successfully passing policy initiatives that have made California’s Tobacco Control Movement 
an example for the nation.  
The success of California’s comprehensive community-based approach is best evidenced 
by the reductions in tobacco prevalence in California among particularly vulnerable 
communities. Data from the California Tobacco Survey3 show significant decreases in adult, 
young adult, and adolescent smoking. Adult smoking prevalence declined from 16.6% in 2002 to 
15.4% in 2004, the second lowest in the Nation. Among young adults, prevalence rates declined 
from 21.3% in 2002 to 18.3% in 2004, and among youth, prevalence rates declined from 16.0% 
in 2002 to 12.2% in 2004 in comparison to the national average youth smoking rate of 22.3% 
(http://www.dhs.ca.gov/tobacco). 
School-Based Cultural Approaches 
Out-of-school youth and young adults are at greatest risk for smoking. Many are reached 
via broad community-level interventions including some of the mechanisms presented above, 
and media campaigns such as the American Legacy Truth campaign,11 which has produced TV 
ads in conjunction with youth to counter pro-tobacco industry influences. 
Schools have been another important vehicle for reaching young people, and are an ideal 
ground for accessing large numbers of individuals that reflect the economic and racial/ethnic 
diversity of their respective communities. Several school-based programs have been shown to be 
effective in particular age groups or in ethnic-specific versus multicultural school settings.  
One such program is Project Fun Learning About Vitality Opinions and Respect 
(FLAVOR) developed for 6th graders in California.12 This project specifically targeted Asian 
and Hispanic/Latino students. The program is a culturally tailored eight-session tobacco 
prevention curricula with a strong theoretical base in social cognitive and social influence 
theories. The program was tested in three types of schools, mostly Asian, H/L and multicultural 
schools along with different conditions. Data show the program was most effective for 
Hispanic/Latinos in mostly Hispanic/Latino schools. The greatest impact was perceived among 
Hispanic/Latino boys in particular. Lessons from Project FLAVOR suggest that although 
nontailored programs can also be effective, there seems to be a greater effect in tobacco 
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prevention when, like Project FLAVOR, the program is not only age specific but also culturally 
tailored. At a time of cost containment, the key is to understand how much tailoring is needed, or 
whether the effect produced by the nontailored program is enough to create the desired changes 
in a targeted population over time. 
The Keepin’ It REAL (Refuse, Explain, Avoid, Leave) program developed by Michael 
Hecht et al.13 is a culturally grounded, classroom-based prevention intervention targeting 
substance use among urban middle-school children (grades 6–8) that has been proven effective. 
The curriculum consists of 10 lessons promoting anti-drug norms, teaching resistance and other 
social skills. Booster activities and a media campaign complement the program. Three versions 
of the program have been produced. These include a Mexican American version, a Black/White 
version, and a multicultural version. The multicultural version was developed by incorporating 
five lessons each from the Mexican American and Black/White versions of the program. Its 
effectiveness in preventing substance use is endorsed by the U.S. Department of Health and 
Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA), 
Center for Substance Abuse Prevention. SAMHSA features Keepin’ it REAL on its Web site as a 
model program (http://www.samhsa.gov). According to SAMHSA, this program has been 
adequately tested and has provided evidence that it is effective in preventing or reducing 
substance use and other high-risk behaviors among Mexican American and Black/White students 
in grades 6–8. 
Other cultural approaches have ranged from adaptations of the Life Skills Training (LST) 
program to Hispanic/Latino-centered and “Afrocentric” approaches developed for and with these 
communities.14,15 Some of the more successful culturally centered approaches have emphasized 
protective factors,9,16–18 such as identifying “anti-drug education,” “extracurricular activities,” 
and “sports participation.” These factors seem to alter attitudes and behaviors about tobacco 
among African Americans. Other interventions have focused on cultural values (“familismo” 
[sense of family as a core value], “respecto” [respect towards elders, figures of authority, etc.]) 
among Hispanic/Latino adolescents or on group consensus building,19 consistent with theories of 
interdependence among Hispanic/Latinos20 and filial piety among Asian/Pacific Islanders.5,18 
Investigators such as Sussman et al.19,21,22,23 have developed effective prevention 
programs especially for high risk populations, such as those in alternative high school settings. 
Although these programs have been used in Hispanic/Latino samples, they have not been 
culturally tailored to this population. Sussman’s Project Towards No Tobacco Use (TNT)23 is a 
tobacco use prevention and cessation program aimed at young teens. Project EX is a tobacco 
prevention and cessation program aimed at older teens. Project EX was tested via a large field 
experimental design. It was found to be effective in preventing tobacco use and increasing 
cessation among older teens. 
The same group of investigators also produced Towards No Drug Abuse (Project 
TND),21 a drug abuse prevention program conducted in south California alternative high school 
system for older teens, particularly for those at high risk for drug abuse (including tobacco). The 
program is composed of nine sessions, including health motivation, social skills, and 
decisionmaking. The curriculum has been scientifically tested among 21 schools that were 
randomly assigned to standard care (control), classroom only, or a classroom plus semester-long 
school–community component. Results of TND revealed significant positive long-term program 
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effects for the program interventions. For example, project TND reduced hard drug use in 46% 
of those who were successfully followed. TND was the first program to demonstrate long-term 
self-reported behavioral effects on hard drug use among high-risk youth by using a school-based, 
limited-session model. Project TND is now considered a model program by the Centers for 
Substance Abuse Prevention, Health Canada, Sociometrics, Inc., and the National Institute on 
Drug Abuse, the Centers for Disease Control and Prevention, Centers for Substance Abuse 
Prevention, and the Department of Education of California. 
Also identified in the literature are other evidenced-based programs that were originally 
developed for non-Hispanic Whites but were later culturally adapted with various degrees of 
success among African Americans and Hispanic/Latinos.19,24,22 The success in implementation of 
these programs has varied in part due to the large differences among youth in identification and 
adherence to cultural norms,5 success of planned versus unplanned tailoring,25 type and degree of 
adaptation, and degree of cultural grounding desired to reach homogeneous or mixed groups in 
the same classroom setting. 
Less scientific evidence is available on the effectiveness of culturally tailored tobacco 
control programs for American Indians and Asian/Pacific Islanders.18,26 Some research points to 
combining skills building with American Indian community conditions with varying effects.26 
For Asian Pacific Islander Americans, programs that address delayed initiation4 and extend 
interventions through young adulthood (18–24 years old) have been favored. 
Thomas, in a Cochrane Collaboration review on school-based programs for preventing 
smoking, identified 16 randomized controlled trials of school-based programs to prevent 
smoking among children who had never smoked.27 A variety of approaches were identified, 
including programs that targeted ethnic minorities and particular cultural groups. Approaches 
ranged from information giving to social influence approaches, generic social skills training, and 
community interventions. In deciding what was most effective, the author did not find much 
evidence that information giving alone, for example, is effective. The review did find overall 
positive short-term effects on children’s smoking behaviors. However, no long-term effects were 
identified. Limited evidence was found on the effects of interventions that included developing 
generic social competence, as well as among those with a multi-modal approach that included 
school and community-based initiatives. The author concludes that although those in the 
intervention groups usually smoked less than the control groups, many studies actually showed 
no effect of the intervention and that there is thus a lack of “high quality” evidence regarding the 
effectiveness of many of these interventions.  
Sifting through the literature, however, one factor that seems to have influenced finding 
positive effects on school and community programs is their comprehensive nature as well as how 
they vary in the adoption of guidelines that lead to reductions in smoking and that increase 
opportunities for cessation.28,29,30 The effects of school combined with community programs 
appear to have the greatest range and more long-term effects on substance abuse rates, and they 
are the only programs to show any effects on parental behavior. Nevertheless, definitive 
conclusions, especially regarding long-term effects of these programs, were not found.27 One 
other finding seems consistent in reviewing cultural approaches: an emphasis on cultural values31 
seems to have an impact on participation and retention in a variety of programs, especially when 




Several cultural approaches to community- and school-based tobacco prevention for 
adolescents and young adults, including priority populations, have been presented. Community-
based culturally specific programs, such as the California Priority Populations Partnerships in 
California, have shown to be effective in countering pro-tobacco influences in communities 
specifically targeted by the tobacco industry, helping to reduce youth and young adult smoking 
rates, including among diverse populations. California’s comprehensive tobacco control program 
has achieved changes in social and cultural norms that favor tobacco and has attained gains in 
reducing second-hand smoke exposure and motivating individuals to quit. Their achievements 
are best exemplified by policies that have passed at the local and State level, resulting in a 60% 
reduction in per capita consumption since the beginning of the program (from 1988 to 2004),3 
and the impact of these policies in reducing the prevalence rates over time. 
In addition to these community-based approaches, successful school-based programs 
have been reviewed. Model programs such as Keepin’ It REAL, Project FLAVOR, and TND 
among others have been presented. These programs have been proven to be successful when 
administered at the appropriate school age level, even though in some, such as TNT and TND 
there has been no cultural tailoring. Other programs such as Keepin’ It REAL and Project 
FLAVOR show the benefits of culturally tailoring a program to its specific target. TND was the 
only program to show long-term effects. 
While multiple school-based interventions report positive effects and have been deemed 
suitable for dissemination, there is not a sufficiently strong body of evidence on cultural 
adaptation or the use of culturally grounded approaches to reach definitive conclusions regarding 
which is more effective in the short and long term. The greater effectiveness of nontailored 
versus tailored and of cultural adaptations or interventions created specifically for priority groups 
is still unclear or nonexistent. For example, we found no published curriculum that addresses the 
specific cultural needs of gay low SES youth of color. Nevertheless, research points to some of 
the highest rates of smoking among youth in these groups. 
The discovery of new interventions, the testing of their effectiveness, and their 
dissemination in particularly vulnerable cultural groups is still needed. Needed also are long-
term population intervention trials that assess the differential impact of culturally grounded 
programs when implemented along the acculturation spectrum or with different populations. We 
know from the literature that many youth and young adults prefer speaking English both at 
school and at home. This is less of an option for newcomers to America with limited English 
proficiency and who may need culturally and linguistic adaptation if we are to adequately reach 
them in a timely fashion. The extent to which cultural adaptations are needed likely depends on 
the extent to which youth identify with their families’ cultures of origin and their ability to speak 
the English language. 
Although we have some insights especially into short-term program effectiveness, more 
research is needed in order to obtain a precise picture of the most effective community- and 
school-based cultural approaches, especially if we are aiming for long-term effects. It is critical 
to also clarify that there are large differences between youth and adults in terms of needs for 
cultural tailoring, mostly based on acculturation status, and that the findings for youth cannot 
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necessarily be extrapolated to those of adult community-based approaches for example. Also 
needed are interventions that focus on approaches among American Indian and Asian/Pacific 
Islander populations and other vulnerable population groups. Large variations within the 
Asian/Pacific Islander community by nativity and acculturation will make this particularly 
challenging.  
It seems that interventions at the middle school level are effective in the short term in 
reducing adolescent smoking. However, dramatic changes in the prevalence occur when children 
reach high school age. This is particularly marked among high-risk, low-SES White and 
Hispanic adolescents. It is still unclear what exactly occurs in that transition period and how we 
can best develop interventions for youth that will have the longest possible lasting effects. If we 
are to argue for comprehensive programs at the school and community level, it is particularly 
important to understand the effect of culture especially on interventions that incorporate a large 
environmental context and that aim at more permanent reductions in adolescent smoking over 
time. 
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Programs and Policies for Prevention 
John P. Pierce, Ph.D. 
Public Health and Smoking Behavior  
Public health mandates to change smoking behavior in the population come from the 
overwhelming evidence of the health consequences of cigarette smoking.1 The major health 
consequence specifically linked to smoking is lung cancer, and its incidence has been 
demonstrated to be a power function of both duration of smoking and its intensity (daily 
consumption level).2,3 Thus, to reduce the health consequences, public health goals are: 
1. Reduce the initial proportion of people who become dependent smokers  
2. Reduce the consumption pattern of dependent smokers 
3. Promote early successful cessation among dependent smokers 
Smoking behavior starts with cognitions about smoking that are observable in U.S. 
residents as young as 10 years old.4 Early experimentation is common in adolescents from 12 to 
14 years old,5 and many people are dependent smokers before they reach the legal age for 
purchase of cigarettes.5 The level of daily cigarette consumption of smokers tends to be higher in 
those who started smoking at younger ages, and this level has been modified by environmental 
and social rules.6 Lower levels of daily consumption are associated with more successful quit 
attempts, although chances of successful quitting are generally low even for those with high 
levels of motivation.  
Effective Tobacco Control Strategies 
There is good evidence to support the use of six tobacco control strategies by public 
health professionals to reduce dependent smoking. These six strategies are: (a) restricting the 
rights of the tobacco industry to market their products, (b) restricting the rights of smokers to 
expose others to secondhand smoke, (c) conducting a mass media campaign aimed at 
denormalizing tobacco use, (d) enforcing laws that ban sales of cigarettes to minors, (e) 
increasing excise taxes to increase cigarette price and reduce demand, and (f) including effective 
smoking education in schools. A comprehensive campaign combines these strategies into a 
single program that can achieve results that far outweigh those of the individual strategies alone. 
The first such comprehensive program in the United States was undertaken in California. This 
expert statement will limit its focus to two of the above approaches: (a) tobacco industry 
marketing and (b) comprehensive campaigns. 
Strategy 1: Restrict Tobacco Industry Marketing 
Cigarettes are a legal product in the United States and, as such, manufacturers are entitled 
to use commercial marketing practices to build demand. Marketing is well known to be 




Product presentation includes the size of the package, its functioning in retrieving a 
cigarette, and the colors and text on the package. The standard package size in the United States 
has been 20 cigarettes, and that seems well suited to the size of pockets and purses. Providing 
smaller quantities for sale has been attempted in different countries, but in the United States this 
has been achieved by merchants breaking open packs and selling small quantities of cigarettes.7 
Restrictions on the product have focused on warning labels: the content, minimum text size, and 
color presentation. Two countries are experimenting with requiring graphic depictions of health 
consequences and warnings in large black type on a white background that take up a large 
proportion of the packaging surface.  
Unit price: All else being equal, higher prices lead to reduced demand. However, with 
highly addictive substances, higher prices often result in a resetting of priorities for disposable 
income. It is notable that only a small portion of smokers, apparently, use price as the critical 
determinant of where and which cigarettes they purchase.8 However, there is good evidence that 
the tobacco industry’s use of price-subsidizing promotions in the United States resulted in 
significant increases in the initiation of smoking among 14–17-year-old adolescents.9  
Promotion: The right to advertise tobacco products on television and in other broadcast 
media in the United States was removed in 1971. Following this removal, there was a marked 
decline in incidence of initiation of adolescents 14–17 years old that remained in effect through 
the mid-1980s, suggesting that restricting advertising might be effective in decreasing product 
use in those under the legal age to purchase cigarettes.9 Studies of innovative tobacco industry 
campaigns established to launch products to a new demographic group also demonstrated that 
significant advertising in the mass media could bring new users into the smoking market, and 
that those new users were mainly between the ages of 14 and 17.10,11  
Communication theories suggest that, to be effective, advertising needs to engage 
nonusers with the advertising message so that they become curious about trying the product.12 
These theories argue that there should be a hierarchy of effects in which the target individuals 
who were receptive to the advertising message were not only exposed to it, but liked the message 
and acted to demonstrate that liking. Such receptivity is correlated with smoking behavior.13 It 
predicts which committed never smokers (CNS) will experiment with smoking over a 3-year 
period,14 as well as which CNS will be adult smokers 6 years later.15 As predicted by advertising 
theories, adolescents who are receptive to cigarette brand advertising were also more likely to be 
curious about smoking, increasing the probability of experimenting with smoking.16 The growth 
of this evidence in the mid-1990s on the effectiveness of tobacco marketing in encouraging 
adolescents to start smoking led to further restrictions on the marketing practices of the tobacco 
industry as part of the negotiated Master Settlement Agreement between tobacco companies and 
State Attorneys General in 1998.17,18 Ecological evidence of the effectiveness of these 
restrictions is that they coincided with a downturn in adolescent smoking following 10 
consecutive years of increasing rates. This evidence is consistent in a number of surveillance 
data sets, the most popular of which is the Monitoring of the Future Surveillance System, which 
has monitored smoking behavior in a random sample of high school students every year since 
1976.19  
Placement in movies also is a well-recognized form of marketing. The price of this 
advertising varies with the character who uses the product (a hero using a product is priced the 
 
39 
highest) and whether or not use of the product helps with the plot.20–22 There are now two 
longitudinal studies that demonstrate that young adolescents whose favorite movie stars smoke 
on screen or who are exposed to a large number of movies portraying smokers are more likely to 
start smoking.23,24  
Strategy 2: Conduct Comprehensive Tobacco Control Programs 
Tobacco control programs are community-wide programs aimed at reducing tobacco 
usage. Early evidence of success of community programs appeared in the 1970s with the 
Stanford Three Communities Project, in which multiple behaviors were targeted.25 The first 
statewide program that focused only on tobacco was conducted in Sydney, Australia and used 
the majority of its budget to purchase mass media advertising. It was shown to effectively reduce 
prevalence.26–28 Comprehensive statewide programs were introduced in the United States in the 
1990s. The goal of the California program (1990–present) was to change the social norms 
surrounding tobacco so as to impact all smoking behavior. While the Massachusetts program 
(1993–2002) included youth programs, they were more focused on encouraging smokers to quit. 
Florida introduced a comprehensive program (1997–2002) aiming only to prevent youth from 
starting to smoke. All of these programs used mass media advertising as a central core of their 
interventions. California was the only program to use legislation requiring smoke free 
workplaces and school campuses to protect nonsmokers. Starting in 1996, California 
aggressively enforced laws restricting minors’ access to tobacco. Massachusetts endeavored to 
protect nonsmokers through mass media messages and community action. Florida was set apart 
by its innovative use of media events to mobilize youth. Both California and Massachusetts 
provided support for cessation using smokers’ helplines.  
All three programs were carefully evaluated, and each was demonstrated to reduce 
smoking behavior. The campaigns in both California and Massachusetts have been evaluated as 
reducing smoking prevalence29,30 and all three programs have been evaluated as reducing 
adolescent smoking initiation.31–35  
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Policy Interventions and Surveillance 
Jean Forster, Ph.D., M.P.H.; Rachel Widome, Ph.D.; Debra Bernat, Ph.D. 
1. Policies To Restrict Exposure of Youth and Young Adults to Environmental 
Tobacco Smoke 
Clean indoor air (CIA) policies are Federal, State, local, and institutional policies that 
prohibit smoking in specified public places such as workplaces, schools, daycare centers, and 
healthcare facilities. While CIA policies have been in existence for more than 30 years, the 
number, strength, and breadth of these laws have dramatically escalated in recent years, even in 
such difficult locations as bars, restaurants, and blue-collar worksites. Almost 500 cities have 
adopted CIA policies covering workplaces, restaurants and/or bars, and 13 States have adopted 
100% smoke-free workplaces, including bars and restaurants.1  
The primary purpose of these policies is to reduce the health risks of environmental 
tobacco smoke (ETS) exposure. The adverse health effects of ETS exposure are thoroughly 
discussed in a recent report from the California Environmental Protection Agency, which labeled 
ETS as a toxic air contaminant based on these effects. For children, ETS exposure is causally 
associated with developmental problems such as low birth weight and sudden infant death 
syndrome; respiratory illnesses, such as bronchitis and pneumonia; chronic respiratory 
symptoms; asthma induction and exacerbation; and middle ear infections.2 These problems are 
all less likely to occur and/or relieved by reducing exposure to ETS. 
In addition, growing evidence suggests that CIA policies can have a powerful negative 
effect on smoking uptake by adolescents. These laws can reduce the visibility of role-models 
who smoke, limit the opportunities for youth to smoke alone or in groups and to exchange 
cigarettes with other smokers, and diminish the perceived social acceptability of smoking.3 A 
number of studies show that smoking bans in the home, at school, at work and in the community 
are associated with less progression to smoking, less consolidation of experimental into regular 
smoking, and more quitting among adolescents.4–6 
2. Policies To Restrict Youth Access to Tobacco 
In the 1992 Synar Amendment, Congress mandated that all States and territories must 
enact laws that prohibit the sale of tobacco to minors and enforce these laws with compliance 
checking.7 Despite delays in effectively implementing the requirements of Synar, sales to minors 
as measured by Synar-mandated compliance checks have decreased nationwide since State laws 
went into effect.8 Additionally, research has shown that youth sales can be reduced through 
active enforcement of these laws.9–15 However, research examining whether these policies reduce 
youth smoking has yielded mixed results. Several early studies found that active enforcement can 
reduce youth smoking;13,16–18 other examinations have found little no effect.14,15,19 Certainly, 
youth access policy is more likely to be effective if enforcement is consistent and uniform in 
geographically contiguous areas. 
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Some believe that, even if youth access policies limit adolescents’ commercial access to 
cigarettes, youth will simply substitute social sources for commercial sources.19,20 An increase in 
the use of social sources has been linked to greater commercial restrictions.17,21 Of teens who 
smoke, it is the heavier smokers who are most likely to provide to other teens, either as a gift or 
for money.22 Wolfson et al. postulates that this is due to the fact that being a heavy smoker may 
be at least partially based on having the greatest access to cigarettes, including commercial 
access.22 
Another tactic aimed at reducing youth access is penalizing youth for possession, use, 
and purchase (PUP) of tobacco. Most tobacco control advocates do not favor emphasizing PUP 
policy because they feel it reinforces the tobacco industry messages that tobacco is for adults, 
and implies that the individual holds sole responsibility for choosing to smoke.23 Currently there 
is no evidence that PUP enforcement reduces youth smoking rates. 
3. Tobacco Excise Tax 
Product-specific (excise) taxes are levied on tobacco products (in addition to applicable 
sales taxes) at the Federal, State, and some local levels. The Federal tax on cigarettes is currently 
39 cents per pack; State excise taxes range from 7 cents (South Carolina) to $2.46 (Rhode Island) 
and averages 92.3 cents per pack (median 79 cents per pack).24 The range of State excise taxes 
reflects recent large increases enacted via statewide referenda and as a solution for recent budget 
shortfalls in many States. Since 2002, 41 States and the District of Columbia have adopted 57 
excise tax increases, averaging 48 cents for each increase.25 
Decades of econometric research show that smokers are price-sensitive, and that 
increasing the price of cigarettes reduces demand. Most reports indicate that adolescents are at 
least as price-sensitive as adults; however, most of the studies were conducted over a narrow 
range of taxes considerably lower than current excise taxes. Also, youth smoking behaviors are 
often less intense and habitual compared to adult smoking, and thus their responses to price 
potentially less predictable. The largest effects of price are seen in heavier smokers, older age 
youth, and males,26–29 which is consistent with reports that young, experimental, and female 
smokers obtain most of their cigarettes from social sources, and are least likely to purchase 
cigarettes.30  
A series of papers using the Monitoring the Future longitudinal data from 1978 to 1994 
found a stronger effect of price for young adult smoking than for adult or adolescent smoking. 
Daily, moderate, and heavy young adult smoking are all negatively correlated with the price of 
cigarettes, as are smoking cessation and regression to lighter smoking.29,31  
4. Tobacco Use Surveillance Systems 
Tobacco surveillance includes ongoing data collection to assess tobacco use at a given 
time and to monitor trends over time. These data are critical for tobacco use prevention, as they 
are used to guide research, public health programming, and public policy. Current best practices 
for tobacco control include participation in national and State surveillance systems.32  
Several surveillance systems track tobacco use among adolescents and young adults 
nationally. These surveillance systems include the Youth Risk Behavior Surveillance System, the 
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Behavioral Risk Factor Surveillance System, the National Survey on Drug Use & Health, and the 
Monitoring the Future Survey. The only national surveillance system devoted solely to assessing 
tobacco use and related attitudes and beliefs is the National Youth Tobacco Survey.33 This was 
the first national survey to provide estimates of tobacco use for middle school students. This 
survey was administered in 1999, 2000, and 2002 and was a joint effort of the CDC and the 
American Legacy Foundation. All of these surveillance systems are designed to monitor tobacco 
use nationally, and several are also designed to provide State-specific estimates.  
Several States have also implemented State surveillance systems to monitor youth 
tobacco use, primarily through the use of school-based surveys. For example, California 
administers the California Student Tobacco Survey, a biennial survey administered to 7th, 9th, 
and 11th grade students, to monitor statewide trends in tobacco use.34 Minnesota also administers 
a statewide survey to 6th, 9th, and 12th graders every 3 years to assess tobacco use.35 
Given the importance of surveillance systems for tobacco use prevention, planning for 
continued surveillance is critical. Several issues warrant consideration. First, many surveillance 
systems rely on telephone surveys. Responses to telephone surveys, however, have declined in 
recent years, due to advances in telephone technology and cellular phone use.36 Thus, new 
methodologies for conducting surveillance may need to be considered. Another focus for future 
surveillance systems will be examining prevalence rates and trends in communities.  
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Increasing Consumer Demand for Effective Tobacco 
Cessation Treatments:  
The Promise for Breakthrough Innovation 
C. Tracy Orleans, Ph.D. 
More U.S. adults have quit smoking than remain current smokers. But 44.5 million 
(20.9%) continue to smoke, with the highest rates among low-socioeconomic status (SES) and 
racial/ethnic minority populations.1 Although 70% of adult smokers want to quit, and as many as 
40% make a serious quit attempt each year, only 20–30% report using an effective behavioral 
counseling or pharmacological treatment (e.g., nicotine replacement therapy, bupropion) able to 
double their quitting success rates.2,3 Lowest rates of treatment use are seen in populations with 
highest rates of tobacco use.3,4 Increasing smokers’ demand for and use of evidence-based 
cessation treatments represents an extraordinary opportunity to extend lives and reduce 
healthcare costs and burden and represents our single best hope of reaching the Healthy People 
2010 adult smoking prevalence goal of 12%. The push-pull-capacity model5 offers a framework 
for understanding this opportunity in the context of broader cancer control research-to-practice 
efforts.6  
Science Push 
The scientific platform for efforts to expand cessation treatment use and reach has never 
been stronger. Formal clinical practice guidelines based on over 6,000 articles have identified 
practical, evidence-based, and cost-effective interventions (psychosocial and pharmacologic) that 
can be delivered in a variety of settings and modalities (e.g., healthcare, community, quitline, or 
online) and individually tailored or targeted to the needs of priority populations.2 This highly 
credible scientific evidence has been widely promoted to healthcare providers, health plans, 
policymakers, and advocates and has furnished a compelling rationale for new policies and 
treatment benefits.4 But it has been much less well communicated to consumers—smokers and 
their families. Recent survey and focus group data reveal wide public uncertainty about the value 
of these treatments, difficulties discriminating effective and ineffective aids and approaches, and 
broad misconceptions about the harms of nicotine replacement therapy (NRT) use.3 The advent 
of new medications (i.e., varenicline, rimonabant), a 2007 guideline update (and the promotional 
opportunities both will bring), and the growth in consumer-directed health plans make this a 
critical time for innovative, theory-driven research to explore consumer treatment needs, 
expectations, and decisionmaking processes, and to develop communications strategies that will 
boost the appeal and use of treatments that work.  
Delivery Capacity 
Policymakers and healthcare and tobacco control leaders have made great strides in 
expanding the capacity to deliver effective treatments. An increasing number of national, State, 
and professional groups (medicine, nursing, pharmacy, dentistry, mental health, and cessation 
specialists) offer cessation-related training and assistance to deliver brief cessation advice and 
treatment.7,8 The proportion of health plans using some system to identify smokers has risen 
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from 15% in 1997 to 71% in 2002. Roughly two-thirds of smokers currently report physician 
advice to quit, advice that is associated with increased use of effective therapies, though only 
38% actually receive them.3,8–11 Advances in health information technology are rapidly 
expanding capacity for computerized reminder systems that boost delivery of counseling and 
medication in “5A” primary care interventions.12 Quitlines, now available nationwide through a 
single toll-free number, have given smokers and providers an unprecedented, barrier-free conduit 
to effective counseling.7,8,13 Growth in online services and the over-the-counter availability of 
NRT products also have increased treatment access.3 While declining public and private funding 
for State and local tobacco control threatens this progress, tobacco cessation advice and 
treatment are now metrics in national healthcare quality, and pay-for-performance initiatives will 
provide new incentives for their delivery as part of routine primary care and new opportunities 
for research to identify healthcare systems and policies that boost treatment use and quit 
rates.2,4,5,10,11,12 
Consumer and Market Demand 
Without consumer demand, or “market pull,” neither strengthening the science base nor 
increasing delivery capacity will yield optimal use of effective cessation treatments. Population-
based policies recommended by the Centers for Disease Control and Prevention12 (CDC) to 
increase quitting and/or treatment use (i.e., clean indoor air laws, tobacco tax increases, reduced 
out-of-pocket treatment costs, cessation media campaigns) are reaching unprecedented numbers 
of smokers, strengthening the norms, supports, and incentives for treatment use. Comprehensive 
clean air laws now cover more than 25% of the population; average combined State and Federal 
cigarettes taxes have reached $1.30 per pack and continue to rise; 41 State Medicaid programs 
and 98% of U.S. health plans provide coverage for some form of counseling or 
pharmacotherapy; and both Medicare and the Department of Veterans Affairs (VA) cover 
cessation counseling.8 Cessation media campaigns, including those that target underserved 
minority smokers, have been found to increase quitting, quitline calls, NRT use, and the use of 
underused treatment benefits, and are a vital counterweight to the billions spent on tobacco 
advertising each year, including for products marketed as “reduced harm” products.3,5,13–15 Huge 
demand can be unleashed when these strategies are combined. Aligning a strong clean indoor air 
law and high tobacco taxes with promotion of free quitline counseling and nicotine replacement, 
the New York City Department of Health achieved an 11% 1-year citywide quit rate and an 
immediate decline in heart attack rates.3,7 These results are compelling evidence for the promise 
of population-based efforts to boost consumer treatment use and demand, and a powerful 
incentive for investment in needed quitting resources and for research to understand how best to 
design, align, and even incentivize coordinated approaches combining policies, treatments, and 
promotions. 
Boosting market demand also requires promotions and incentives aimed at employers, 
insurers, and health plans—powerful intermediary “consumers.” New evidence and tools 
establishing the “business case” for tobacco dependence treatment and the inclusion of tobacco 
use screening and treatment in national pay-for-performance quality metrics bring new 
prospects.8,9,16 But insurers and employers also place great weight on direct employee and 
enrollee request,14 adding to a growing imperative for innovations to improve the ways in which 
evidence-based treatments are designed and delivered, so that they have greater consumer appeal 
and better engage quitters across their full quitting journeys. One of the most exciting new 
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frontiers in tobacco cessation research and practice involves applying design principles and 
processes used to build demand for other consumer products to meet this challenge.17 Early 
findings of the national Consumer Demand Roundtable suggest that this approach could lead to 
major breakthroughs in treatment use and impact, and in the Nation’s prospects for achieving its 
Healthy People 2010 tobacco goals. 
Translating Research to Practice and Policy:
Science Push, Capacity Building, and Market Pull 
GOAL:  To increase the delivery, reach, use, and impact of evidence-based tobacco cessation treatments  
Pull: Creating demand 
for tobacco cessation 
and effective treatments
Push: Proving, improving 
and communicating  
treatments for wide 
population use
Building the capacity of
healthcare and other 







Standards for defining 




in new populations or 
settings
Research to develop more 
effective, feasible, and 
replicable interventions
Communications and 
advocacy  geared to key 
decisionmakers and end-
users—e.g., health plan 
leaders, providers, 
employers/insurers, 
policy makers,  the public
Provider training, education, TA
Engineering systems-level 
supports (e.g., information and 
reminder systems to identify 
tobacco use,  prompt screening 
and treatment , quitlines, on-line/off 
visit; Rx to OTC) 
Performance measurement and  




strategies that increase 
quitting and treatment use 
(e.g., clean  indoor air laws, 
tobacco tax increases, co-pay 




making the business case  
Redesigning treatments to 
increase consumer appeal, 
engagement, and use (tailored 
to individuals/target groups)
Connecting the dots—linking 
treatments, policies, and 
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Increasing Demand for and Use of Cessation Treatments 
Among Low-Income and Blue-Collar Populations 
Elizabeth M. Barbeau, Sc.D., M.P.H. 
This abstract addresses the question: What are effective strategies for increasing 
consumer demand for and use of proven, individually oriented cessation treatments among 
low-income and blue-collar populations? Smoking prevalence remains high among individuals 
of lower socioeconomic position, whether measured by income, occupation, or educational 
attainment. In 2000, prevalence of current smoking among blue-collar workers was 35.4%, 
compared to 20.5% among white-collar workers.1 Likewise, smoking among individuals with 
incomes below the Federal poverty threshold was 34.7% compared to 20.7% for those earning 
three times the poverty threshold.1 Blue-collar and low-income smokers attempt to quit as often 
as their more advantaged counterparts, but they are less likely to succeed.1 The relative lack of 
success may be due, in part, to lower use of proven cessation treatments. According to data from 
the 2000 National Health Interview Survey, smokers with lower incomes and less education were 
less likely to use proven cessation treatments (counseling and/or pharmacotherapy as specified in 
the Public Health Service (PHS) guidelines) compared to those with higher incomes and more 
education (table 1). These patterns were evident for both genders, Blacks and Whites, but not for 
Hispanics, who were represented in small numbers in this survey.     
A key assumption embedded in the question addressed in this abstract is that 
pharmacotherapy and counseling are proven cessation treatments across all social classes. This 
abstract thus focuses on synthesizing current knowledge and critical scientific gaps regarding 
effective strategies for increasing consumer use of and demand for these proven treatments. 
Potential strategies for increasing demand for and use of treatments can be divided into two 
broad categories: reducing barriers to use of treatments and promoting use of treatments.  
Reducing Barriers to Use of Treatments Through Health Insurance Programs 
Out-of-pocket expenditures for counseling and pharmacotherapy can pose financial 
barriers to their use. Insurance-based financial coverage for smoking cessation treatments is one 
way to lower this barrier, and empirical evidence to date indicates that insurance-based coverage 
increases use of smoking cessation treatments. In a comparison of different levels of coverage 
within a large health maintenance organization over 2 years, Curry et al. found that the use of all 
cessation services was greater with full coverage than with cost-sharing plans (11.6% vs. 3.5–
3.7%).2 In a randomized control trial of 1,204 smokers who received either a self-help kit or fully 
covered benefits for nicotine replacement therapy (NRT)and behavioral counseling, Schauffler et 
al. found that full coverage of benefits resulted in significantly higher use of NRT (25% vs. 14%, 
p=0.001).3 In a similar study in the Netherlands, Kaper et al.4 randomly assigned 1,266 smokers 
to an intervention group, which received an offer of reimbursement for nicotine replacement 
therapy, bupropion and behavioral counseling, or to a control group, which received no offer of 
reimbursement. During the reimbursement period, 10.8% of smokers in the intervention group 
reported having used a smoking cessation treatment, compared to 4.1% in the control group 
(Odds Ratio [OR]=2.9, 95% Confidence Interval [CI] 1.8–4.7). None of the possible effect 
 
54 
modifiers, including educational attainment and income, modified the effect of reimbursement 
on the use of treatments.  
With respect to low-income smokers, Medicaid is an important insurance vehicle through 
which to assess strategies for increasing demand for and use of proven cessation treatment. In 
2000, approximately 32 million low-income persons in the United States received their health 
insurance coverage through the Federal/State Medicaid program; approximately 11.5 million 
(36%) of these persons smoked.5 Cummings et al. reported that use of the NRT patch increased 
by 57% among Medicaid recipients when full financial coverage was provided, even after 
adjusting for other sociodemographic differences.6  
Labor-management health and welfare funds provide health insurance to 10 million 
unionized workers, largely in blue-collar occupations, and their dependents. Ringen et al. 
reported that, when a pilot smoking cessation program involving telephone counseling and 
pharmacotherapy was offered free of charge to a population of unionized blue-collar workers 
through their health and welfare fund, 944 of 7400 (13.4%) of smokers insured enrolled in the 
program within 2 years.7   
In summary, a small, but convincing, empirically based literature indicates that increasing 
financial coverage of tobacco cessation treatments through insurance programs would likely lead 
to increased use of proven smoking cessation treatments. Medicaid and labor-management health 
and welfare funds are particularly important insurance channels through which to reach low-
income and blue-collar workers, respectively. Important areas for future research are identifying 
effective intervention strategies at individual and organizational levels to: (1) increase demand 
for and purchase of these benefits among individual- and group-level insurance purchasers and 
benefits administrators, (2) increase demand for these services among insurance plan 
participants, and (3) increase utilization by plan participants once benefits are in place.  
Promotions  
Cessation treatments can be promoted in a variety of channels, including television, 
radio, and print media; the internet; and community-based settings (e.g., unions, worksites, 
churches, Women, Infants, and Children [WIC] programs). There is a dearth of studies using 
randomized controlled trial designs to evaluate the relative effectiveness of different promotion 
strategies (or promotion vs. no promotion) on the outcome of increasing demand for or use of 
treatments among low-income and blue-collar smokers. For example, according to a recent 
review of telephone quitline promotion practices, extant literature has described promotion as an 
important element of quitline programs, but promotion itself has not yet been studied as an 
independent variable.8 A randomized controlled community-based trial of the effectiveness of a 
media campaign to increase use of the National Cancer Information Service among African 
Americans reported that use of the service was higher among residents in the intervention vs. 
control communities.9 No similar study exists for low socioeconomic (SES) groups. Likewise, 
promotion of pharmacotherapy treatments has not been well studied. Pharmaceutical firms that 
sell these medications may have information about the relative effectiveness of various 
promotion and advertising strategies on increasing sales, but these findings do not appear in the 
peer-reviewed literature.   
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A new area of research ought to be established to investigate the effectiveness of various 
promotion strategies for increasing demand for and use of cessation treatments for the general 
population of smokers and, most especially, for groups remaining at high risk of smoking, 
including low-income and blue-collar populations. Research is needed to identify effective 
messages and channels through which to disseminate those messages in order to achieve 
maximum impact on increasing demand for and use of proven cessation treatments. Such 
research will necessarily involve multidisciplinary teams of researchers with expertise in 
communication science, health education, behavioral science, and tobacco control, undertaking 
both qualitative and quantitative research using RCTs and quasi-experimental study designs.   
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Table 1. Age-Adjusted Prevalence of Use of Tobacco Cessation Aids Among U.S. 
Current Adult Smokers Who Attempted To Quit for 1 Day or Longer by 
Sociodemographics Characteristics, National Health Interview Survey 2000. 
  Use of Cessation Aids 
 Sample 
N=3,218 % (s.e.) 
Chi-square
p-value 
Overall prevalence  22.5 (0.9)  
Socioeconomic characteristics:     
Age: 
 18–34 years 
 35–54 years 




























Years of completed education:* 
 Less than a high school degree  
 High school degree 
 Some college or college graduate 
 
Years of completed education and sex* 
 Males  
 Less than a high school degree  
 High School degree 
 Some college or college graduate 
 
 Female 
 Less than a high school degree  
 High School degree 




























































Table 1. Age-Adjusted Prevalence of Use of Tobacco Cessation Aids Among U.S. 
Current Adult Smokers Who Attempted To Quit for 1 Day or Longer by 
Sociodemographics Characteristics, National Health Interview Survey 2000. 
(continued) 





Race/ethnicity and education: 
 White NH  
 Less than a high school degree  
 High school degree 
 Some college or college graduate 
 
 Black NH  
 Less than a high school degree  
 High school degree 
 Some college or college graduate 
 
 Hispanic 
 Less than a high school degree  
 High school degree 















































Family annual household income:* 
 $20,000 or more per year 
 <$20,000 per year  













Race/ethnicity and family household income: 
 White NH 
 $20,000 or more per year 
 <$20,000 per year  
 
 Black NH 
 $20,000 or more per year 
 <$20,000 per year  
 
 Hispanic 
 $20,000 or more per year 






































(%)*=Age adjusted weighted prevalence  
Recommended tobacco cessation therapies, includes counseling therapies alone and/or pharmacological therapies 
(nicotine replacement therapies, and Zyban/Bupriopion/Wellbrutrin), as recommended by the PHS Clinical Practice 
Guidelines.  





Evidence-Based Practice Center Presentation:  
Increasing Demand for and Use of Effective Tobacco 
Cessation Treatments Among Individuals 
Cathy L. Melvin, Ph.D., M.P.H. 
Background 
For those individuals who become dependent on tobacco products, eventual disease, 
disability, and death for themselves and those around them can be avoided if they quit using 
these products. Users dependent on tobacco find that quitting is very difficult, although most of 
them would like to do so.1 Proven individual strategies for helping smokers to quit include 
counseling and behavioral therapy, and, except when contraindicated, the use of first-line and 
second-line medications.2 More often than not, individuals are trying to quit without assistance 
that can double their chances of success.2  
Methods 
Using the analytic framework in figure 1, we undertook a systematic review of the 
evidence for interventions aimed at increasing the number of smokers who attempt to quit and 
improving the impact of individually oriented treatments developed to help them quit using 
tobacco products (“key question 2” in the main evidence report). 
Figure 1. Increasing Demand for and Use of Cessation Interventions Among 
Individuals: Analytic Framework 
 
We searched standard electronic databases (MEDLINE®, the Cumulative Index to 
Nursing and Applied Health [CINAHL], Cochrane Collaboration libraries, Cochrane Clinical 
Trials Register, Psychological Abstracts, and Sociological Abstracts) between January 1, 1980, 
and June 10, 2005 (for this question, relevant inclusion dates were January 1, 1999, through June 
10, 2005). We used Medical Subject Headings as search terms, when available, or key words 
when appropriate. We limited our review to (1) human studies conducted in developed countries 
and published in English; (2) studies with participants ages 13 and older, of both sexes, and 
diverse racial and ethnic populations; (3) randomized controlled trials (RCTs) with 30 or more 
individuals; (4) observational studies and other trials with 100 or more individuals; (5) studies 
with a minimum followup period of 6 months, with or without comparison groups. We excluded 
editorials, letters, and commentaries; articles that did not report outcomes related to our key 
questions; and studies that did not provide sufficient information to be abstracted. For earlier 
 
60 
work on these matters, we relied on prior systematic reviews.2–8 If studies already in those 
reviews addressed the same outcomes of interest (i.e., increased quit rates; greater number of 
smoking cessation participants), we did not re-abstract data. We reviewed and extracted data that 
met our inclusion criteria from studies published after the existing reviews; we entered the data 
into evidence tables and summarized them by descriptive methods. From our review of 639 
abstracts, 22 studies addressed the demand for and use of effective tobacco cessation treatments; 
we rated 5 studies as poor quality and do not discuss them further. Seven eligible studies focused 
on strategies to increase the number of users who attempt to quit; 10 focused on interventions 
aimed at improving the success rate of quit attempts.   
Results: Increasing Demand for Cessation Treatment  
Our review of multicomponent strategies to increase the number of users who attempt to 
quit included telephone counseling as a strategy. Findings from recent reviews show that 
proactive telephone counseling is effective in increasing tobacco use cessation for adults, 
especially when combined with other counseling formats. Four studies of fair quality focused on 
telephone counseling with related print materials.9–12 As a group, these studies yielded 
insufficient and inconsistent evidence to draw conclusions about the efficacy of telephone 
counseling. When considered within the context of recent systematic reviews and meta-analyses, 
two studies11,12 in our review were consistent with that body of evidence; each demonstrated a 
positive effect of telephone counseling along with relevant print materials on quitting smoking.  
The evidence showing that telephone counseling targeting youth and young adults 
achieved quit rates comparable to those shown for adults is promising, but the small number 
(two) of fair studies is insufficient to draw conclusions on the effect of telephone counseling for 
this population.10,11 
We found no studies evaluating multiple counseling formats. One study evaluating 
counseling enhanced by the provision of information on genetic susceptibility to lung cancer 
showed a short but un-sustained effect on cessation rates.13 Results of studies evaluating 
persistence of effect in the long term were inconsistent.14,15  
Results: Improving Success of Cessation Interventions 
Our review of strategies to improve the success of quit attempts identified 10 studies 
evaluating the efficacy of self-help strategies, counseling, and pharmacotherapies, including 
combination pharmacotherapy, fluoxetine, and bupropion in an indigenous population; all were 
of fair quality.16–25 Our findings for self-help strategies were consistent with those of earlier 
reviews: evidence of the effectiveness of self-help strategies was insufficient, given the 
inconsistency of effects and the small number of studies.21,22 
Our review of interventions using counseling strategies produced mixed results. Two 
studies showed increased abstinence rates,19,25 but two other studies showed no effect of 
counseling on cessation rates.16,23 These findings were insufficient on their own to make a 
recommendation differing from earlier reviews that conclude that even brief individual cessation 
counseling is efficacious. 
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With respect to pharmaceutical approaches to increasing quit attempt success, we 
reviewed two trials of combination pharmacotherapy17,20 that showed an increase in long-term 
(i.e., 12 months) cessation compared with one pharmacotherapy alone. Although insufficient in 
number and quality to draw definitive conclusions, these studies shed light on the use of 
combination therapies and suggest the need for additional research to replicate these findings. 
This is especially important because participants in these trials reported fewer side effects and 
withdrawal symptoms, both factors that could increase the likelihood of quitting smoking.  
In one trial of fluoxetine (a selective serotonin-reuptake-inhibiting antidepressant) as an 
adjunct to cognitive behavioral counseling, investigators found that fluoxetine increased the 
likelihood of abstinence, as compared with placebo, among smokers with minor depression but 
not among those with little or no depression.18 Although these results may be promising for 
medication-compliant smokers with subclinical levels of depression, they need to be replicated in 
other studies that help us to understand the moderating effect of depression on fluoxetine 
responsiveness and the characteristics of those smokers most likely to benefit from fluoxetine. 
In a study of whether bupropion combined with smoking cessation counseling was 
effective in treatment of tobacco use in indigenous Maori in New Zealand, the investigators 
found quit rates similar to those observed in other trials of bupropion24 and reported no data to 
suggest that the Maori encountered any special problems related to bupropion use.  
Conclusions and Needs for Future Research 
Very few studies examine the relative population impact of various proven cessation 
interventions. For example, knowing how proactive telephone counseling support compares with 
a face-to-face intervention, or whether or not nicotine replacement therapy is offered, would be 
useful. Differential rates of enrollment and success on a population basis may offset or enhance 
each other. These research questions are especially important given the move toward increased 
provider referral to quitline services. 
We found no studies comparing the specific aspects of telephone counseling with each 
other. Issues around the number and timing of calls and the role of feedback to the caller’s 
primary provider have not been studied sufficiently.  
We did not identify sufficient studies of the role of mass media in driving people to 
quitline and other cessation services. Research on specific messages and their effectiveness in 
reaching and motivating target audiences such as adolescents, young adults, and persons with 
low income and educational status should improve the impact of such interventions. 
We found very few studies examining the effectiveness of multiple intervention formats, 
of combination pharmacotherapy, or of adjuncts other than pharmacotherapy to individual 
counseling in increasing the success of smoking cessation interventions. Similarly, very few 
studies examined differences in either withdrawal symptoms or side effects associated with 
continuation or success of pharmacotherapy. Persistence of effect was reported by only two 
studies; larger, prospective trials are likely needed to increase the evidence base for this issue. 
Finally, very few studies focused on ways to reach or treat special populations such as 
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Health Systems Changes 
Michael C. Fiore, M.D., M.P.H. 
In 1996, the Agency for Health Care Policy Research (AHCPR, now the Agency for 
Healthcare Research and Quality [AHRQ]) released the first Federal clinical practice guideline 
for smoking cessation.1 Both the 1996 AHCPR guideline and the 2000 Public Health Service 
update were innovative in that they identified six evidence-based strategies for healthcare 
systems to facilitate the institutionalization of tobacco dependence treatment. These strategies 
are:  
• Implementing a tobacco-user identification system in every clinic  
• Providing education, resources, and feedback to promote provider intervention  
• Dedicating staff to provide tobacco dependence treatment and assessing the delivery 
of this treatment in staff performance evaluations  
• Promoting hospital policies that support and provide tobacco dependence services 
• Including all tobacco dependence treatments (both counseling and pharmacotherapy) 
identified as effective as paid or covered services for all subscribers or members of 
health insurance packages 
• Reimbursing clinicians and specialists for delivery of effective tobacco dependence 
treatments and including these interventions among the defined duties of clinicians2  
Systems-level strategies represented a new way of thinking about treating tobacco 
dependence. Typically, interventions have targeted either the smoker or the clinician. In contrast, 
systems strategies are designed to ensure that tobacco use, the leading cause of illness and death, 
is addressed in a more systematic way. The goal of these strategies is straightforward—to ensure 
that tobacco use is systematically assessed and treated at every clinical encounter. Since these 
recommendations were first released in 1996, new research has expanded the scientific basis for 
systems changes, including reviews conducted by the U.S. Public Health Service Task Force on 
Community Preventive Services as well as the Cochrane Collaboration.3–6 Moreover, an 
evaluation conducted by the Cancer Research Network found that the adoption of health plan 
policies can result in the implementation of systems-level changes and increased delivery of 
these services to patients.7 Examples of progress in some of these areas and future opportunities 
for research and implementation are summarized below. 
Implementation of Tobacco-User Identification Systems in the Clinic Setting 
There is significant evidence that implementing a clinic-based tobacco-user identification 
system increases the rate of smoker identification and facilitates provision of advice to quit and, 
possibly, assistance in quitting.8–11 Recent research further describes the positive impact of 
including tobacco use as a vital sign on rates of asking about smoking status.12,13 Findings from a 
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periodic survey of health plans conducted by America’s Health Insurance Plans (AHIP) show 
that the percentage of health plans that were able to identify any individual members who smoke 
increased from 14.9% in 1997 to 71.7% in 2002 (p<0.001).14  
Improvements in rates of clinician intervention also are seen in national data sets. The 
2004 Health Employer Data and Information Set (HEDIS) data collected by the National 
Committee for Quality Assurance (NCQA) documented that 69.6% of commercial enrollees, 
66.9% of Medicaid enrollees, and 64.7% of Medicare enrollees reported receiving advice to quit 
smoking, compared to 66.3% of commercial enrollees, 64.2% of Medicaid enrollees, and 59.3% 
of Medicare enrollees in 2000.15 
Providing Education, Resources, and Feedback to Clinicians 
There is significant evidence that multicomponent interventions that incorporate both 
provider education and reminder systems facilitate delivery of evidence-based tobacco 
dependence treatments.3 A review on audit and feedback in clinical practice published by the 
Cochrane Collaboration found that these strategies can improve provider performance, but 
improvements are small to modest. The effects of audit and feedback were likely to be larger 
when initial performance was low.4 New research has helped expand the evidence base 
surrounding performance feedback, demonstrating both that providers will accept such feedback 
and that feedback can increase the performance of targeted behaviors.16–18 
Hospital Policies That Support Inpatient Cessation Services 
A 2003 Cochrane review evaluated the effectiveness of smoking cessation interventions 
for hospitalized patients, finding that high-intensity behavioral interventions that included at least 
1 month of followup were effective in increasing the delivery of smoking cessation treatments to 
inpatients.6 In 1992, the Joint Commission for Accreditation of Healthcare Organizations 
(JCAHO) issued a standard requiring that all accredited hospitals have a policy prohibiting 
smoking in the hospital; by 1994, more than 96% of hospitals surveyed complied with the 
JCAHO standard, and 41.4% had enacted policies that were stricter than the JCAHO standard.19 
In 2002, for the first time, JCAHO added performance measures for adult smoking cessation 
advice and counseling for patients presenting with acute myocardial infarction (AMI), 
community-acquired pneumonia (CAP), and heart failure (HF) to its core performance measure 
set. From July 1, 2004, to June 30, 2005, national rates for providing advice or counseling were 
89% (AMI), 78% (HF), and 75% (CAP).20 
Include Efficacious Tobacco Dependence Treatments in Insurance Packages 
Over the last 15 years, there has been a substantial increase in the coverage of tobacco 
dependence treatments by publicly funded insurance programs. In 2005, Medicare began 
covering cessation counseling for recipients diagnosed with a tobacco-related illness, and in 
2006, prescription cessation medications were covered through the Medicare Prescription Drug 
Act (Medicare Part D). A growing number of State Medicaid programs provide some coverage 
for tobacco cessation, with 37 States covering at least one evidence-based treatment in 2003.21 In 
2006, the Department of Veterans Affairs (VA) eliminated copayments for cessation counseling. 
Increases in coverage are also seen in the private market. A periodic survey conducted by AHIP 
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found that plans reporting full coverage for any behavioral therapy or pharmacotherapy increased 
from 75% in 1997 to 98% in 2002.14 A Cochrane review evaluated healthcare financing systems 
for increasing the use of tobacco dependence treatment. The authors found that there was some 
evidence that offering full coverage of tobacco dependence treatments can increase self-reported 
prolonged abstinence rates at relatively low costs when compared with a partial benefit or no 
benefit; however, methodological limitations require that these findings be interpreted with 
caution.5 
Lessons Learned and Future Directions 
Systems changes have the potential to increase rates of tobacco-user identification and 
intervention, and subsequently to improve the health of patients by facilitating quit attempts. 
While much progress has been made, further work is needed to ensure that all tobacco users are 
identified and receive evidence-based treatment for tobacco dependence each time they present 
to the healthcare system. This goal is particularly salient given that 70% of smokers visit a 
primary care physician each year. A number of researchers have identified healthcare systems 
questions for further exploration, including:3,22  
• Systems approaches such as tobacco-user identification are successful in improving 
documentation of patients’ tobacco use, but do not necessarily spur further 
intervention. What strategies can be implemented and evaluated to foster provision of 
advice and, particularly, the delivery of evidence-based treatment? 
• What are the most and least effective combinations of services in multicomponent 
interventions? 
• How effective are the HEDIS and JCAHO measures in improving patient receipt of 
advice to quit and patient tobacco use cessation? What would be the impact of a 
JCAHO requirement mandating that tobacco use be addressed for all hospital 
admissions? 
• How does the base rate of tobacco use in a managed care organization or insurance 
plan affect implementation of systems-level changes and outcomes? 
• How can mixes of tobacco use cessation interventions be most effectively integrated 
in managed care organizations?  
• What are the costs, cost-benefit, and return on investment of systems-level 
interventions?  
• How can technologies such as registries and electronic medical records be used to 
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Addressing Tobacco-Related Disease Health Disparities in 
the Delivery of Community-Based Interventions 
Phillip Gardiner, Ph.D. 
To address the question of tobacco-related disease health disparities and which 
community-based interventions have worked is no small task. Moreover, while tobacco 
prevention and cessation efforts are certainly necessary, ultimately they may be in and of 
themselves insufficient to fully address the chronic concentration of morbidity and mortality of 
tobacco-related disease in poor communities, special populations, and communities of color. 
It should go without saying that the existing community interventions must not only 
collect data, but also bolster a community’s capacity to tackle tobacco-related disease health 
disparities. Community-based researchers cannot just show up and “intervene” in communities; 
rather, researchers have to become part and parcel of the community and, together with 
community residents, transform the community’s relationship with tobacco products and 
mitigate their impact. Toward this end, what we know about community-based interventions is 
addressed below, and one road forward that could get at the root of the disparities themselves is 
discussed. 
What We Know 
Two excellent review articles have assessed the effectiveness of tobacco control and 
cessation efforts in communities of color.1,2 Lawrence et al. discovered that interventions in 
communities of color were more or less equally divided between those taking place in clinical 
settings, on the one hand, and those located at specific locations (e.g. school) and/or community-
wide interventions, on the other hand. Of the 36 interventions reviewed by Lawrence and her 
team, 14 (39%) reported significant reductions in the use of tobacco products. Additionally, she 
found that quasi-experimental studies were proportionately more successful than the randomized 
experimental studies. Lawrence also found that media and culturally tailored materials were used 
in the majority of interventions reviewed.  
Okuyemi and colleagues, in their review of 43 studies that reported on smoking cessation 
in racial and ethnic populations, found a clear dose-response relationship; intensive interventions 
produced higher success rates and were more cost effective.2 This team found that intensive 
interventions may include pharmacotherapy multiple individual or group sessions, telephone 
counseling, self-help materials, and followup assessments. Interestingly, both the Lawrence and 
the Okuyemi reviews showed that the majority of the studies have focused on African Americans 
and smoking, and Lawrence points out that it would be incorrect to generalize findings from 
experiences in this population linearly to other communities of color. While it is true that most 
studies dealing health disparities have focused on African Americans, it is also unfortunately true 
that African Americans suffer disproportionately from tobacco related diseases, including the 
highest incidence and death from lung, oral, pancreas esophagus and larynx cancers.3 
There are, and continue to be, some successful community-based interventions to reduce 
smoking among communities of color. In the African American community, Ahluwalia et al. 
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have shown that community-based cessation programs using nicotine replacement therapy 
(NRT) or bupropion can decrease smoking rates.4,5 Ricardo Munoz, working in the 
Latino/Hispanic community through a mood management program, cut smoking 25.4% for 
intervention subjects compared to 9.2% of controls.6 Similarly, Woodruff and colleagues were 
able to successfully use a promotores-modeled intervention where intervention participants’ 
abstinence rate was 20.5% compared to 8.7% for controls.7 Jenkins et al., implementing a 
community-based intervention, were successful in lowering the odds of being a smoker among 
Vietnamese Americans living San Francisco.8 
Not only are there successful community-based interventions taking place around the 
country to thwart the impact of tobacco use among disparate populations, but also the United 
States Federal Government, through the agency of the National Cancer Institute, has issued a 
lengthy list of research recommendations, including increased funding of community-based 
research, training and mentoring of researchers representing underserved racial and ethnic 
groups, and research on the impact of the tobacco industry’s practices and policies in oppressed 
communities.9 Still, in all, model replicable interventions to tackle tobacco health impacts in 
separate communities are few and far between. 
Undeniably, the “California experience” has conclusively demonstrated that a focus on 
changing social norms, prioritizing underserved communities, and establishing a statewide 
infrastructure that connects grassroots local organizations are key ingredients to reduce tobacco 
use.10,11 Moreover, the California experiment has also shown that a focus on indoor and outdoor 
smoking policies, regular and systematic exposure of the deceitful and illegal practices of the 
tobacco industry, and an aggressive media campaign can have a tremendous impact. The fine 
work of the Tobacco Control Section of California’s Department of Health Services, along with 
the efforts of both the Tobacco Use Prevention and Education program of the California 
Department of Education and the Tobacco Related Disease Research Program of the University 
of California Office of the President, has brought this State’s smoking rates down to 15% of the 
adult population, second only to Utah.12,13 It also must be noted that another societal-wide 
intervention has been shown to be effective in increasing the accessibility of cessation services 
and education to disparate groups—the quitlines that have proliferated throughout the country 
based on the California experience.14  
Yet, for all the advancements made by California, other States, and numerous successful 
community-level and State-level interventions, tobacco-related disease health disparities persist 
and endure. African Americans continue to die disproportionately from lung cancer, coronary 
heart disease, cerebrovascular disease, and oral cancer, to mention a few.15 For American Indians 
and Alaska Natives, smoking rates stubbornly remain around 40% of the adult population.15 
Vietnamese male smoking rates continue above 50%, and, increasingly, Asian and Pacific 
Islander women coming to the United States have begun the long deadly journey to adopt 
cigarette smoking, although slowly.16  
It goes without saying that if it took years, nay decades, to produce and reproduce 
tobacco-related disease disparities, then it will take decades to overcome them. However, it will 
be of the utmost importance to tackle the problem correctly; band-aids and half steps will only 




An Alternative Framework 
To effectively and systematically identify, reduce, and ultimately eradicate 
tobacco-related disease health disparities, community capacities will have to be substantially 
increased; the participatory nature of research, regardless of the type of community, must 
become the norm; and environmental disparities including racialized marketing on the part of the 
tobacco industry stopped.   
First and foremost, communities must have increased capacity to tackle runaway 
tobacco-related disease disparities. Robert Robinson has argued persuasively over the years that 
communities of color must have a mass infusion of resources if tobacco-related health disparities 
are going to be effectively addressed.17 It is no secret that large parts of the African American, 
Latino, American Indian, and immigrant Asian and Pacific Islander populations are mired in 
poverty. Communities lack cessation services, clinics, hospitals, pharmacotherapeutics, and 
general medical resources of all kinds. Even more broadly, communities lack health insurance 
and employment opportunities that ensure health coverage. True; there are, and should continue 
to be, successful prevention and cessation interventions taking place in the context of poor 
communities. It is also true that many communities of color have not and are not idly sitting by 
waiting for salvation; some have taken steps to right their own community’s ship of health in a 
clearly unrelenting storm. However, unless and until these communities are lifted up and brought 
into the mainstream, the conditions that spawn and promote tobacco-related disease health 
disparities will persist. 
Secondly, those interventions that, of necessity, take place in poor disparate communities 
must be participatory in nature. Gone are the days (or I should say the days should be gone) 
when researchers and investigators showed up in a community, shook a few hands, collected a 
lot of data, published their findings in narrowly read scientific journals and left. The involvement 
of the community in all aspects of the research is a must. From the identification of issues; the 
conceptualization of the research questions and hypothesis; writing and submitting grant 
applications; hiring of staff and the implementation of the intervention; collection of data and the 
analysis of the results; and the dissemination of findings across a broad array of venues and 
media—community members and researchers must jointly participate in the process.18 Moreover, 
community-based tobacco cessation and control interventions must take place in the actual 
context of the disparate conditions faced by many communities. Severe poverty, poor education, 
lack of fresh foods, nonexistent open areas, and deteriorated and segregated housing all are part 
of the milieu in which research must take. Simply said, larger sociostructural issues cannot be 
avoided, nay must be addressed, when tackling the question of tobacco-related disease health 
disparities in many communities of color. 
Thirdly, major tobacco marketing and advertising restrictions must be implemented in 
communities that suffer disproportionately from tobacco-related diseases. If, for example, 
African Americans die disproportionately of lung cancer, then it behooves society to restrict as 
much as possible the promotion of tobacco products in that community. Tobacco company 
advertising in this context is like throwing gasoline on a raging fire. The tobacco industry’s 
forays into special populations in the guise of market segmentation advertising must be severely 
curtailed. In an ideal world, each human being should be able to make rational decisions about 
what they consume. However, in the real world, communities of color are bombarded with 
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messages about the sexiness and/or manliness of tobacco use, and, coupled with the 
extraordinarily addictive character of cigarettes, it is nothing short of a recipe for disaster. 
Some may feel that the some of the suggestions made above fall outside the realm or 
reach of community-level interventions to stem the tide of tobacco use; in some respects, they 
do. At the same time, those working in poor and marginalized communities must not only 
approach community residents about “their use of tobacco,” but conversely must struggle to 
understand the conditions and issues that contextualize the use of tobacco products. Without 
doing this, any and all tobacco cessation projects will have limited success and be short lived at 
best; true community-based participatory research requires a long-term, societal-wide 
commitment.  
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QUITLINES: Public-Private Partnerships for Tobacco Control 
Tim McAfee, M.D., M.P.H. 
Background 
Quitlines (QLs) provide a broad range of cessation support services primarily via the 
telephone. Services range from a single reactive coaching session provided at the time a caller 
reaches the QL to multiple proactive counseling calls originating from the service provider over 
time. Most counseling is provided by paraprofessionals following a semi-structured protocol 
blending elements of several counseling theories (Stages of Change, Motivational Interviewing, 
Cognitive-Behavioral Therapy) with practical evidence-based advice and encouragement. 
Increasingly, cessation medication is being integrated into service provision,1,2 ranging from 
screening and decision support to fulfillment via direct mail order or pharmacy vouchers.3 A 
strong evidence base supports QL efficacy and effectiveness.4 A 2004 Cochrane Review5 found a 
1.56 odds ratio (OR), overlapping with the nicotine replacement therapy (NRT) OR confidence 
interval.6 
Table 1. Efficacy of NRT and Telephone Counseling (TC)—Cochrane Reviews 
 Odds ratio (95% CI*) Average sample size/trial 
NRT (n=98) 1.74 (1.64, 1.86) 385 
TC (n=13) 1.56 (1.38, 1.77) 1,100 
*Confidence Interval  
QLs often provide brief coaching to proxy callers such as friends and relatives, as well as 
healthcare providers. They also provide cessation materials and referral to local resources. Less 
research has been done on the effectiveness of these functions. 
Significance 
QLs help increase the reach of evidence-based services by increasing convenience and 
anonymity and by providing multilingual services.7 They improve linkages between 
pharmacotherapy and behavioral and adherence support. They enhance population quit rates in 
clinical practices (e.g. from 4.1% to 13%8), worksites, and geographic regions, both by direct 
effects for those calling as well as by secondary effects9 such as inspiring quit attempts in 
noncallers exposed to promotion and encouraging legislators to continue funding 
multicomponent tobacco control programs. Some populations underrepresented in cessation 
treatment are overrepresented in State QL calls, such as the uninsured10 and African Americans. 
How Delivered 
There is wide variation in who QLs serve, and how they are delivered and financed. QLs 
have been set up to deliver services in municipalities, counties, and States and at the national 
level. They also have been set up to provide services to health plans, employers, and unions. QLs 
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are delivered by a wide variety of service providers, including academic and healthcare 
institutions, governmental and philanthropic organizations, and private companies. Financing for 
the services is quite varied, including: State funding from tobacco taxes, Master Settlement, and 
general funds; health plan benefit coverage; employer coverage as a “carve-out;” Federal funding 
to support State services; and philanthropic support underwriting indirect service costs, serving 
special populations and promotion. Based on evidence that end-user payment markedly 
decreases use,11 very few QLs charge users. 
There are increasingly sophisticated public-private partnerships extending the depth and 
breadth of services offered. Integration occurs at the State level, with another layer at the 
national level. Currently, 46 States have operational QLs, with the remainder expected to be 
operational in 2006. However, some of these QLs are supported completely by limited Centers 
for Disease Control and Prevention (CDC) funding. The National Cancer Institute (NCI) and 
CDC have collaborated with States to create a national network of QLs, all with a single number 
(1-800-QUITNOW), available as a portal that routes calls back to their respective State QL. 
Some States are further collaborating with health plans and businesses that provide and/or fund 
indepth telephonic coaching services and full pharmacotherapy. In these States, callers are 
triaged by the State-level QL with warm transfer to the service provider for the health plan or 
employer. The State line conserves limited resources for the provision of full proactive service 
and pharmacotherapy for the uninsured. States that do not have this form of relationship 
frequently titrate the amount of promotion done to ensure they have sufficient funds to provide 
service to callers.  
These ambitious, complex partnerships have been fostered by the creation of a North 
American Quitline Consortium12 which includes Federal agencies such as NCI and CDC, State 
health departments and State-level foundations, service providers, and researchers. Limitations 
have included heterogeneity of funding at the State level, with some States providing limited 
services (i.e. a single call) with minimal promotion, while some provide robust promotion and 
services (either through direct provision such as Maine, or via public-private partnerships). Call 
rates range from less than 1% of smokers per year7 up to over 8%13 at the State level. Some 
employers have reached into the 20% level, when combined with incentives.  
Another limitation of QLs is lack of awareness by smokers of their existence and 
effectiveness.14 In 2006, the American Legacy Foundation will run several pilots of an ambitious 
mass media campaign that will include promotion of the 1–800–QUITNOW number. If 
successful, this will be followed by a national media campaign. 
Challenges for the Future 
The National Action Plan15 anticipates that with unfettered access to counseling and 
pharmacotherapy coupled with robust promotion, 10% of smokers per year would use services 
with a 20% quit rate. This is a 5- to 10-fold increase over current use rates. From experience, this 
number appears achievable with improved funding and infrastructure development. 
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There are promising innovations that could increase reach, effectiveness, and efficiency 
even further. These need additional development and research:  
1. Using chronic care/disease management approaches with QLs: 
• Proactive outreach to high-risk populations where smoking status may be 
available. Initial results indicate >50% acceptance rates 
• Long-term follow-up and open-ended treatment, e.g. recurrent status checks with 
offers of re-enrollment for those who have relapsed16  
2. Integration of phone services with other remote communication vehicles: 
• Web-based tailored content and social interaction via chat and discussion 
functions, with iterative quit plan development tools 
• Text messaging, cell phones, e-mail 
3. Further integration and innovation of pharmacotherapy and QLs: 
• Further experiments in promotion effects of brief courses of NRT 
• Tighter relationships with healthcare providers for prescription generation 
• Interrelationships between medication and coaching 
• Testing of safety, efficacy, and practicality of aggressive med approaches, 
including combination and higher-dose therapy, initiation while smoking, new 
medications, “test kits,” and aggressive medication management  
4. Impact of “Ask-Advise-Refer” model with QLs used for referral on clinic system 
adoption versus traditional “5-A” model17 
5. Developing and testing improved and new behavioral interventions: 
• Device-supported fading 
• Different theoretical approaches: CBT, MI, “3 Ts”18 
• Increasing call frequency or call time  
• Relapse-sensitive vs. recycle-sensitive timing of calls 
6. Incentive programs such as “quit & win” and decreased health insurance premiums  
7. Cost-effectiveness of different promotional & service approaches: 
• Quantify quit attempt increases from mass media vs. healthcare promotion 
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• Cost Effectiveness Analysis and Return on Investment for likely high-yield 
populations such as Chronic Obstructive Pulmonary Disease and obstetrics 
8. Development and testing of proxy interventions.19 Can ex-smokers and nonsmokers 
improve basic support skills and serve as more competent resources to motivate and 
then support smokers attempting to quit?  
9. Experiments in coordination of public-private benefits to increase reach: 
• Risk-based sharing of financing for service and promotion 
• Aggressive government-funded service—how does this impact health 
plan/employer financing and delivery? 
10. Sub-population tailoring of promotion and service 
Finally, QLs are creating a remarkable infrastructure for theoretical and applied research 
in numerous disciplines. They are collecting uniform minimum datasets on hundreds of 
thousands of tobacco users attempting to quit each year. There is wide heterogeneity in 
recruitment and service strategies from State to State and institution to institution, providing 
numerous natural experiments. Because of the high volume of participants and computerized 
coaching support, QLs also provide opportunities for “easy” large-scale social science, health 
services, pharmacologic effectiveness, and other randomized trials to test theoretical models as 
well as to conduct practical clinical trials relating to cost effectiveness and equivalency of 
different approaches. 
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Changing Product/New Tobacco Delivery System 
Dorothy Hatsukami, Ph.D. 
Tobacco prevention and cessation are the most effective methods to reduce mortality and 
morbidity associated with tobacco use. However, because so many smokers are unable or 
unwilling to quit smoking at any one time, reducing—rather than eliminating—harm associated 
with tobacco use has been considered as a potentially viable alternative intervention method.1 
Methods to reduce exposure and potentially reduce risk for disease include reducing the amount 
of tobacco use, modifying tobacco products and/or using specialized filters for cigarettes to 
reduce toxicant levels, heating rather than burning a tobacco product, or switching from 
combustible to noncombustible products. Although the number of studies that have examined 
these potentially reduced exposure products (PREPs) are limited,2 it is becoming apparent that 
the potential for harm reduction from combustible products is unlikely. Although products that 
contain solely nicotine (and that are regulated) will produce the least harm of all PREPs, oral 
noncombustible products may also lead to reduced harm relative to cigarettes. Compared to 
cigarette smoking, smokeless tobacco use is associated with significantly lower morbidity and 
mortality, has less potential for addiction, and is associated with higher rates of cessation than 
cigarettes.3 However, these results do not suggest that smokeless tobacco is safe and that it does 
not produce addiction. The use of these products has been associated with oral pathologies, 
including oral cancers, as well as pancreatic cancers.4,5 Nonetheless, on an individual risk basis, 
smokeless tobacco has a significant potential to reduce harm. On the other hand, it is uncertain if, 
on a population basis, smokeless tobacco as a method to reduce disease might in fact increase 
potential harm by increasing the prevalence of tobacco use—particularly if smokeless tobacco is 
a gateway product for cigarette smoking—by encouraging continued use rather than cessation, or 
by resulting in high incidence of dual use of products with consequent greater toxicity. The fact 
that the public health impact depends not only on the physical characteristics of the products but 
also on how they are used, misused, and how their use affects other product use, is part of the 
reason that caution was urged by the Institute of Medicine Committee,1 and currently by the 
World Health Organization (http://www.who.int/tobacco/communications/events/wntd/2006/ 
rationale/en/index.html). 
Nonetheless, research on the addiction potential and toxicity across different smokeless 
tobacco products, particularly reduced-nitrosamine products, is essential to determine the 
potential of these products for reduced exposure and reduced harm. Various smokeless tobacco 
products have also been evaluated for amount of nicotine.6,7 Table 1 shows the studies that 
describe amounts of nicotine, the pH levels, and percent-free nicotine: the higher the pH, the 
greater the availability of free or bioavailable nicotine, which is more readily and quickly 
absorbed than ionized nicotine. To date, several studies have examined the amount of toxicants, 
particularly tobacco specific nitrosamines (TSNAs).8,9 TSNAs are the most significant 
carcinogens in smokeless tobacco and cigarettes.10 Two of these constituents, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-nitrosonornicotine (NNN), are 
carcinogenic in laboratory animals.10 Both these carcinogens have been evaluated by the 
International Agency for Research on Cancer as carcinogenic to humans (Group 1).5 A more 
recent study was conducted that shows TSNAs in more novel products as well as medicinal 
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nicotine (see table 2).9 The results show that medicinal nicotine contains minimal or nonexistent 
levels of TSNA. Ariva, a tobacco lozenge, also contains low levels of TSNA. Exalt and Revel, 
which are being marketed to smokers, contain relatively higher levels of TSNA, and the most 
popular brands of smokeless tobacco sold in the United States contain the highest levels among 
the products tested. A few studies have been conducted in humans. Figure 1 presents a summary 
of the various studies that examined the uptake of one of the TSNAs, as measured by 4-
(methylnitrosamino)-l-(3 pyridyl) l-butanol (NNAL) plus its glucuronides (total NNAL), 
metabolites of the tobacco-specific carcinogen, 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone 
(NNK). The results in humans paralleled the TSNA product studies. Interestingly, the lowest 
levels of total NNAL were found with medicinal nicotine, and similar levels were observed for 
Ariva. As expected, the highest levels were found with Copenhagen and Skoal.  
Several methods exist to determine addiction potential for tobacco products. These 
include examining nicotine pharmacokinetics, with the product producing the fastest and highest 
peak being associated with higher addiction potential. In addition, subjective responses to the 
products will also be informative. Figure 2 shows the nicotine pharmacokinetics across 
conventional smokeless tobacco products.11 The most popular products show the highest and 
fastest delivery of nicotine and also produce the most subjective responses. Another method to 
test addiction potential is to have individuals sample products and then provide them a choice of 
the product to use. Two studies were conducted, one examining Ariva vs. a medicinal nicotine 
lozenge and another examining Exalt vs. a medicinal nicotine lozenge. The results showed the 
Ariva was used more frequently than medicinal nicotine, however, no preference was 
demonstrated for Exalt over medicinal nicotine.12 
More research examining these novel products that include the types of testing described 
in figure 3 is necessary.13 These studies should involve identifying and examining the effects of 
any new constituents. In addition, human clinical trials need to be conducted that are longer term 
and involve both naturalistic use of products—to determine patterns of use and resulting toxicant 
exposure—and sole use of the product. Conducting these trials would involve identifying reliable 
and valid biomarkers for exposure and toxicity. In addition, studies need to be conducted that 
assess consumer perception of these novel products and the impact of marketing claims on this 
perception. Research is also necessary to ensure the relative risk of products is conveyed in a 
way that is accurately interpreted. Finally, surveillance that examines prevalence of use of these 
products, the pattern of use, and consequences of use is necessary.  
In summary, of all the novel PREPs and methods for reducing cigarette consumption, 
with the exception of medicinal nicotine, novel oral noncombustible products that contain low 
toxicant levels are likely to lead to reduced harm in smokers. Although medicinal nicotine is the 
safest product, because of the current regulatory environment, medicinal nicotine undergoes 
rigorous testing, is manufactured to be acceptable but not attractive in its own right, and thus is 
unlikely to produce addiction (and therefore sustained use) compared to the tobacco products, 
and tends to be high in cost. No such regulation is available for tobacco products. Therefore, 
regulation of tobacco products is essential to accurately inform consumers of the extent of 
toxicity of various tobacco products, to reduce toxicant levels in all tobacco products, and to 
render “the playing field” equivalent for tobacco and medicinal nicotine products. Research 
should be conducted toward this end and toward the end of providing the methodology and 
measures for tobacco regulation. 
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Table 1. Nicotine Content of Smokeless Tobacco Products 
Dose Product PH 
Nicotine 
Content mg/g Free Nicotine (%) 
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Table 2. Tobacco-Specific Nitrosamines in Products9  
Product µg/g product (wet weight) 
 NNN NNK NAT NAB Total 
New tobacco products      
Hard snuff      
Ariva 0.019 0.037 0.12 0.008 0.19a 
Stonewall 0.056 0.043 0.17 0.007 0.28b 
Spit-free tobacco packets      
Exalt      
Purchased in Sweden 2.3 0.27 0.98 0.13 3.7c 
Purchased in United States 2.1 0.24 0.68 0.05 3.1b 
Revel      
Mint flavored 0.62 0.033 0.32 0.018 0.99b 
Wintergreen flavored 0.64 0.032 0.31 0.017 1.0b 
Tobacco-free snuff      
Smokey Mountain nd nd nd nd ndb 
Nicotine replacement therapy products 
NicoDerm CQ (patch, 4 mg nicotine)e nd 0.008 nd nd 0.008b 
Nicorette (gum, 4 mg nicotine)e 0.002 nd nd nd 0.002b 
Commit (lozenge, 2 mg nicotine)e nd nd nd nd ndb 
Conventional tobacco products      
Smokeless tobacco      
General 0.98 0.18 0.79 0.06 2.0d 
Copenhagen      
Snuff 2.2 0.75 1.8 0.12 4.8b 
Long cut 3.9 1.6 1.9 0.13 7.5b 
Skoal      
Long cut straight 4.5 0.47 4.1 0.22 9.2b 
Bandits 0.9 0.17 0.24 0.014 1.3b 
Kodiak      
Ice 2.0 0.29 0.72 0.063 3.1b 
Wintergreen 2.2 0.41 1.8 0.15 4.5b 
a Mean of 5 analyses, each performed in duplicate 
b Single analysis performed in duplicate 
c Mean of 3 analyses, each performed in duplicate 
d Mean of 2 analyses, each performed in duplicate 
e Values are expressed per piece 
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Figure 1. Total NNAL Concentrations Across Different Brands of Smokeless 
Tobacco12,14  

























Figure 2. Mean Plasma Concentration, Heart Rate, and Total Visual Analogue Score 
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Policy Perspective for Tobacco Risk Reduction  
Lynn T. Kozlowski, Ph.D. 
Leashing the “Pussycat” While the “Lion” Runs Free: The Problematic Mismatch 
of Regulations and Product Risks 
In the United States, the least dangerous (and not very dangerous) form of nicotine 
delivery system, nicotine replacement therapy products (NRTs, or “medicinal nicotine”), has 
been subject to close, science-influenced oversight by the U.S. Food and Drug Administration 
(FDA), while the most dangerous (and extremely dangerous) nicotine delivery system, the 
cigarette, has been exempted from FDA and even Consumer Product Safety jurisdiction. 
Furthermore, cigarettes are advertised widely in magazines, their makers can add to their 
reputation in national advertising campaigns on television in prime time, and cigarettes can be 
readily, though illegally, bought at relatively low cost by even the marginally enterprising 12-
year-old. Smokeless tobacco products, especially those with high levels of cancer-causing 
nitrosamines, are also exempted from drug and product laws. Much to the chagrin of many anti-
tobacco advocates, the risks of manufactured smokeless tobacco products in the United States or 
Sweden, especially those with low nitrosamine levels, are much closer to the risks of NRTs than 
they are to cigarettes.1,2 Smokeless tobacco products are dangerous (NOT SAFE) products, but 
they are undoubtedly less dangerous (SAFER) products than cigarettes.  
Population Harm and Smokeless Tobacco—Using the Risk/Use Equilibrium 
Even though smokeless tobacco is less dangerous to individual users than cigarettes, if 
many more people start using the product, is it likely to produce a net loss for public health? This 
has become a frequent question when considering the population effects of less dangerous 
products for individuals. To get a sense of scale for the possible problems caused by increased 
use of a less dangerous product, we employ what we call the risk/use equilibrium—an 
equilibrium achieved by increasing use as risk decreases.3 Figure 1 plots the equilibrium line—
the level at which a decrease in risk is made equal to the initial risk by virtue of an increased 
number of users. If the level of use rises faster than risk is decreased, public health would be 
hurt. If risk levels are decreased faster than use rises, public health would be helped. Figure 1 
plots the relationship between level of risk and the increase in the number of users (as a 
multiplier) needed to achieve equilibrium, or, in other words, no increased population-level risks.  
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Each point on this curve indicates the multiplier needed to achieve a constant level of 
population risk, given specific levels of decreased danger per user. For example, if 100 
individuals used a product with full danger (e.g., killing 100% of users), 10 times that 
number (1,000 individuals) would need to use a product that had 90% decreased 
danger, to achieve an equal health problem (100 dead in each instance). The formula is 
Y=100/100-X, where Y=Multiplier and X=Decrease in Danger, expressed in 
percentages. If danger is 0.1%, use would have to increase by 1,000 times to produce a 
problem of the same magnitude as the full-risk product (not plotted on figure). For a 
given risk on the curve, use that is increased by a smaller multiplier represents a public 
health benefit, and use that is increased by a larger multiplier represents a public health 
(population-level) cost. 
Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV. Applying the risk/use 
equilibrium: Use medicinal nicotine now for harm reduction. Tobacco Control. 
2001;10:201–203. 
In 2003, a British Royal College of Physicians expert committee concluded that 
smokeless tobacco is from about “10–1,000 times less hazardous than smoking, depending on 
the product.”4 While it is difficult to determine the precise level of risks to health from smokeless 
tobacco products, it is likely to be substantially less dangerous than cigarettes, especially for low 
nitrosamine products.2 It is reasonable to assume that very low nitrosamine products could be 
about 1,000 times less hazardous than smoking, which, according to the risk/use equilibrium 
would indicate very little chance for net public health harm. 
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The Specter of Smokeless Tobacco as a Causal Gateway to Cigarettes 
Another concern has been that, even if smokeless tobacco is less dangerous than 
cigarettes, if smokeless tobacco use leads to (is a causal gateway) to cigarettes, then the reduced 
risk is, in a sense, only transitory. A “correlational gateway” between smokeless tobacco and 
cigarettes is easy to find evidence for, but a “causal gateway” in which prior use of smokeless 
tobacco causes an increased probability of smoking is much more challenging to prove. Some 
experts have argued that smokeless tobacco use in youth may lead to subsequent cigarette 
smoking;5 others have argued that smokeless tobacco may even act to prevent cigarette smoking 
in high-risk youth, and that much of the association between smokeless and smoking is not 
causally linked.6,7 But it is also true that marketing and prevention efforts to reduce cigarette 
smoking should be able to decrease the possible progression from smokeless to cigarettes. 
Mistaken public health information that smokeless tobacco is as dangerous or even more 
dangerous than cigarettes (see below) may actually promote the movement to cigarettes by 
smokeless tobacco users.8 
Health Communication Issues on Smokeless Tobacco Products 
The health communication practices on comparative risks of tobacco products on some 
major Web pages have improved recently in the United States. A few years ago, for example, in 
2001, the Centers for Disease Control and Prevention’s (CDC’s) Surgeon-General’s Report for 
Kids asked the question “Is smokeless tobacco safer than cigarettes?” and answered “NO 
WAY!” and the Web page of the Substance Abuse and Mental Health Administration’s 
(SAMHSA’s) National Clearinghouse for Alcohol and Drug Information2 contained this passage: 
“Q. Isn’t smokeless tobacco safer to use than cigarettes? A. No. There is no safe form of 
tobacco.” (accessed August 14, 2002).8 Kozlowski and O’Connor8 raised issues about the 
science base of such prominent public information on smokeless and questioned the ethical 
justification for this disinformation on comparative risks of smoking and smokeless tobacco use. 
There was also a formal complaint under the Data Quality Act that resulted in the National 
Institute of Aging changing the information on its Web site on smokeless tobacco.9 And in 2005 
there was an analysis by Philips, Wang, and Guenzel on the “misleading and harmful public 
message about smokeless tobacco”10 to be found on the Internet. Accessing (or trying to access) 
these pages on March 28, 2006, however, demonstrated some major positive changes in the sites 
mentioned above and, for example, in the American Cancer Society’s Web page. It seems to 
have become less controversial to indicate the established risks of smokeless tobacco products 
and to forgo hyperbole.  
“Not Safe” Is Not Enough 
Health communications should also do more than inform that “there is no safe tobacco 
product.”11 The congressionally mandated rotating warning that “WARNING: This product is 
not a safe alternative to cigarettes” is, in effect, a “not safe” message. At present there is an 
alignment of the basic message from the National Cancer Institute12 and from the Philip Morris 
Tobacco Company13 (on their Web site and in national advertising) that there is no safe tobacco 
product. This message is of course true, but it is also a truism, in that “nothing is completely 
safe,” and it is of limited value in that the public largely knows that there is no safe tobacco 
product.11 One of the lessons of the low-tar-cigarette disaster is that, while the public understands 
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that “low-tar” cigarettes are “not safe,” a public health tragedy has resulted from the 
simultaneous, non-contradictory belief that low-tar cigarettes were “safer” (when they are not).14 
Given the years of mistaken information about the comparative risks of smokeless and cigarettes 
in the United States, there may also be an active need to correct the belief that smokeless tobacco 
is more dangerous than cigarettes.  
Policy Questions 
How important is it to make more dangerous products harder to get? 
Would it be good for population health to adjust the expense (e.g., by taxation), the 
marketing/promotion, and the availability of tobacco/nicotine delivery systems, such that it is 
harder to get more dangerous products and easier to get less dangerous products? Would such 
efforts reduce the sales of the most dangerous products? 
How should cross-product comparisons be done to assess health risk 
differences? 
Based on mortality, smokeless products are less dangerous than cigarettes. It is less 
common to compare on the basis of morbidity or quality-of-life differences. Premature death is 
part of the tragedy of chronic obstructive lung disease; but long-suffering, behaviorally impaired 
years of life are also part of the tragedy. More complete assessments of disease- and disability-
risk differentials are needed and may help motivate smokers to turn away from cigarettes. 
What is the best way to communicate risk differences? 
Research is urgently needed to develop ways to communicate science-based risk 
differentials in ways that minimize deception and maximize the likelihood of choices that benefit 
public health. For example, is it better to avoid speaking of “safer” products and better to 
describe them as “less dangerous” or “less harmful”? 
Why aren’t all smokeless tobacco products sold in the United States meeting a 
very low nitrosamine standard? 
If the United States ever were able to establish a strong, science-based, public-health-
concerned regulatory authority, low nitrosamine levels would likely be required in all smokeless 
tobacco products, to help reduce cancer risks. Even without regulatory oversight, one wonders 
why more manufacturers are not voluntarily reducing levels of nitrosamines in their products. 
Given that some products on the market now contain extremely low levels of nitrosamines, 
might health communication campaigns related to levels of toxic ingredients in smokeless 
tobacco help discourage the use of the more toxic products and even have an effect on the 
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Epidemiological Perspective for Tobacco Risk Reduction 
Scott L. Tomar, D.M.D., Dr.P.H. 
Hundreds of millions of people worldwide are addicted to smokeless tobacco, and use by 
young people is increasing in many countries. The types of product vary widely around the 
world. The common defining characteristics of smokeless tobacco products are that they are not 
burned by the consumer at the time they are used; they deliver nicotine into venous circulation 
through passive absorption across oral or nasal mucosa; and virtually all products contain human 
carcinogens and toxins in levels substantially higher than are typically found in any non-tobacco 
consumer product. 
There has been recent discussion within the tobacco control community concerning the 
role, feasibility, and supporting evidence of a harm-decreasing strategy in reducing the societal 
burden of tobacco use.1 Because of lower risks for morbidity or mortality compared with 
cigarettes, various smokeless tobacco products, particularly moist snuff, have been suggested as 
potential reduced-exposure products for smokers who are unable or unwilling to quit using 
tobacco.2–4  
Compared with the large body of literature on the adverse health effects of cigarette 
smoking, the literature on adverse health effects associated with smokeless tobacco use is far 
smaller and, for some disease endpoints, less conclusive. In part, that limitation reflects the 
nature of smokeless tobacco use in most parts of the world. In general, smokeless tobacco use is 
far less prevalent than smoking in most developed nations, so observational studies that include 
an adequate sample size of exposed persons are more difficult to assemble. In addition, a large 
proportion of smokeless tobacco users in most countries also have a history of using burned 
types of tobacco products such as cigarettes, bidis, or hookahs, a factor that creates challenges in 
identifying cohorts whose only form of tobacco use is smokeless tobacco.  
There have been several recent reviews on the health effects of smokeless tobacco. A 
working group recently convened by the International Agency for Research on Cancer reviewed 
the available epidemiological, animal, and chemical literature. The working group concluded 
there is sufficient evidence that smokeless tobacco causes oral cancer and pancreatic cancer in 
humans, and sufficient evidence of carcinogenicity from animal studies. The working group 
concluded that smokeless tobacco is “carcinogenic to humans.”5 Several large prospective cohort 
studies suggest that smokeless tobacco use may elevate the risk of death from cardiovascular 
diseases,6,7 though several case-control studies did not find a significant association.8–10 There is 
some evidence that smokeless tobacco use increases the risk for adverse reproductive health 
outcomes among pregnant women, including low birth weight, preterm delivery, stillbirth; and 
pre-eclampsia.11,12 Oral health effects include localized periodontal destruction, soft tissue 
lesions, and, possibly, dental abrasion.13 There is compelling evidence that smokeless tobacco 
use can result in nicotine addiction.14  
To date, only one study has explicitly examined the effectiveness of snuff use as a 
smoking cessation method.15 That pilot study found that 16 of the 63 subjects (25%) in the study 
had quit smoking by using snuff at the 1-year followup, and 6 subjects (10%) had quit smoking 
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by using another method. However, this study did not have a control group. In a 7-year followup 
of 62 of the original 63 subjects, 28 (45%) had quit smoking, although fewer than half of the 
subjects (n=12) who had quit smoking in that uncontrolled study reportedly had done so by using 
snuff.16 
Sweden has been cited as the single example in which moist snuff use apparently 
replaced smoking for a proportion of males. The prevalence of daily smoking dropped by 50% 
between 1980 and 2001 among 16–24-year-old males, while their snuff use increased, but the 
same rate of decline in smoking was seen for young women with almost no snuff use.17 The 
pattern of smoking that appears to be emerging in Sweden is a declining but equal prevalence of 
current smoking for men and women, with a greater proportion of male current smokers than 
female smokers reporting smoking less often than daily (figure 1). Based on a cross-sectional 
study of current and former smokers in Sweden,18 the apparent effectiveness of snuff in helping 
smokers to quit is modest at best. Among males, snuff was used in the most recent attempt to 
quit smoking by 28.7% of former smokers and 23.0% of current smokers (p=0.072). Only 4.8% 
of female current smokers in that study who had attempted to quit and 4.5% of female former 
smokers (p=0.85) reported using snuff during their most recent attempt to quit smoking. 
Switching from cigarettes to snuff in Sweden appears to occur primarily among men who had 
prior experience using snuff.10 









































Source: Unpublished data from Swedish ULF Surveys, Statistics Sweden 
Ecological patterns in Norway do not support a substitution effect for snuff on the 
prevalence of cigarette smoking (see figure 2). As in Sweden, snuff use is an almost entirely 
male behavior. The prevalence of snuff use among 16–24-year-old males increased from 9.3% in 
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1985 to 18.6% in 2003, while the prevalence of current smoking remained relatively stable at 
greater than 40% and generally equal for males and females during that period. Snuff use also 
increased among males older than 25 years of age since 1985, but snuff is rarely used by 
Norwegian women; rates of daily or any current smoking remain virtually equal for men and 
women ages 25–34 or 35–44. 
























Males: any current snuff
 
Source: Directorate for Health and Social Affairs (Norway). Tall om Tobakk [number about tobacco]. 1973–2003. 
[Norwegian]. Oslo: Directorate for Health and Social Affairs; 2004. 
There is little information on the proportion of U.S. smokers who have switched 
completely to the use of smokeless tobacco or have used smokeless tobacco as a method of 
quitting smoking. Fiore and colleagues19 reported findings from the 1986 Adult Use of Tobacco 
Survey on the methods smokers used to quit. That study reported that, in the mid-1980s, 6.8% of 
former smokers who successfully quit smoking for at least 1 year had substituted other tobacco 
products (including snuff, chewing tobacco, pipes, or cigars) during any attempt at quitting, and 
4.0% of successful quitters substituted other products during their last attempt at quitting. 
However, the proportions were nearly the same among relapsers: 6.8% of smokers who made a 
serious quit attempt in the past year but were not successful in quitting tried substituting other 
tobacco products in any attempt, and 2.1% tried that strategy during their last attempt at quitting. 
More recent data come from the 2000 National Health Interview Survey, in which former 
smokers were asked what method they had used to quit smoking completely.20 Just 1% of male 
former smokers ages 36–47 reported switching to snuff or chewing tobacco to quit smoking. Of 
male current smokers in that age group who attempted to quit, 0.3% reported switching to 
smokeless tobacco on their last attempt to quit. In a birth cohort in which 16% of males, 
including 19% of those who had ever smoked, had used smokeless tobacco by age 34, smokeless 
tobacco use accounted for a very small proportion of quitting.  
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Smoking is relatively prevalent among smokeless tobacco users in the United States. In a 
nationally representative cross-sectional study, current smoking was reported by 19% of those 
who used snuff every day, 39% of occasional snuff users, and 39% of former snuff users.21 
If smokeless tobacco were used as a substitute for cigarettes in some U.S. States, it might 
be expected that there would be a negative association between the prevalence of smokeless 
tobacco use and cigarette smoking. To the contrary, in multiple linear regression modeling, there 
was a significant positive association between State-level prevalence of smokeless tobacco use 
and cigarette smoking among males age 18 years and older in 1998–2000. 
Smokeless tobacco use remains highly prevalent in India, where oral cancer vies with 
lung cancer as the most common type of malignancy.22 Smoking quit rates are very low in India, 
and there is no evidence that widespread use of the various forms of smokeless tobacco has 
reduced the use of burned tobacco products such as bidis. As in other countries, the initiation of 
smokeless tobacco use in India occurs primarily at young ages.22 
Use of various smokeless tobacco products is widespread throughout South Asia and 
parts of Africa. There is no evidence from these regions that these products have led to 
reductions in cigarette smoking or use of other burned tobacco products. 
In conclusion, the available evidence suggests: (1) the uptake of moist snuff in the United 
States and several European countries during the past several decades has occurred primarily 
among adolescent and young adult males; (2) increased prevalence of snuff use is not 
consistently associated with a reduction in smoking initiation or prevalence; (3) moist snuff use 
apparently plays a very minor role in smoking cessation in the United States and an inconsistent 
role in Sweden; (4) U.S. States with the lowest smoking prevalence also tend to have the lowest 
prevalence of smokeless tobacco use and vice versa; (5) there are no data on the efficacy of snuff 
as a smoking cessation method; and (6) cigarette smoking is fairly prevalent among smokeless 
tobacco users in several countries. The evidence base for smokeless tobacco promotion as a 
public health strategy is weak and inconsistent. 
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Evidence-Based Practice Center Presentation: 
Smokeless Tobacco: The Effects of Product  
Marketing on Use and Population Harm 
Leah M. Ranney, Ph.D., M.A. 
Background 
Smokeless tobacco can lead to nicotine addiction and dependence.1 Evidence from the 
Surgeon General and others has linked smokeless tobacco causally with oral leukoplakia and oral 
cancers.2,3 Two types of smokeless tobacco are sold in the United States: chewing tobacco (i.e., 
loose leaf tobacco, plug, or twist ) and snuff (i.e., finely ground tobacco that can be dry, moist, or 
in sachets).4,5 An estimated 7% of high school students are current users of smokeless tobacco; 
males are the primary consumer.6 Adolescents who use smokeless tobacco are more likely to 
become smokers than adolescents who do not use smokeless tobacco products.7 
Adolescents and young adults continue to be a strategically important market segment for 
the tobacco industry.7 During 2001, the largest tobacco manufacturers spent $236.7 million on 
smokeless tobacco advertising and promotion using images that portray the attractiveness of 
tobacco products.5 Recently, tobacco companies have begun to market their smokeless tobacco 
products as less harmful alternatives to smoking tobacco, likening them to nicotine replacement 
products and emphasizing that smokeless tobacco does not carry risk for others as does smoking 
with second-hand, or environmental tobacco, smoke.8 We believe that it is too early to determine 
if these “harm reduction” approaches to smokeless tobacco marketing are effective in increasing 
its use.  
We undertook a systematic review to investigate three concerns of smokeless tobacco 
product marketing (“key question 4” in the main evidence report), using the analytic framework 
in figure 1. We examined whether (1) substituting smokeless tobacco for smoking results in less 
smoking-related harm on a population basis, (2) smokeless tobacco marketing leads to greater 
use or substitution of smokeless tobacco for smoking (or both), and (3) data on harms and harm 
reduction associated with smokeless tobacco are used to model the potential health effects of 
substituting smokeless tobacco for smoking.  





We searched standard electronic databases (MEDLINE®, the Cumulative Index to 
Nursing and Applied Health [CINAHL], Cochrane Collaboration libraries, Cochrane Clinical 
Trials Register, Psychological Abstracts, and Sociological Abstracts) between January 1, 1980 
and June 10, 2005 using Medical Subject Headings as search terms when available or key words 
when appropriate. We limited our review to (1) human studies conducted in developed countries 
and published in English; (2) studies with participants ages 13 and older, of both sexes, and 
diverse racial and ethnic populations; (3) randomized controlled trials (RCTs) with 30 or more 
individuals; (4) observational studies and other trials with 100 or more individuals; and (5) 
studies with a minimum follow-up period of 6 months, with or without comparison groups. We 
excluded editorials, letters, and commentaries; articles that did not report outcomes related to our 
key questions; and studies that did not provide sufficient information to be abstracted.   
We reviewed all eligible studies, extracted and entered relevant data into evidence tables, 
and summarized findings by descriptive methods. From our review of 639 abstracts, two articles 
addressed marketing of smokeless tobacco products. 
Results: Smokeless Tobacco Product Marketing 
We found no study evaluating whether substituting smokeless tobacco for smoking 
results in less smoking-related harm; similarly, no study can substantiate whether data on harm 
and harm reduction associated with smokeless tobacco are used to model the potential health 
effects of substituting smokeless tobacco for smoking. In addition, no prior systematic reviews 
addressed these issues. The absence of data on substituting smokeless tobacco for cigarettes is 
striking.   
Two studies with quality ratings of fair focused on the smokeless tobacco use.9,10 They 
investigated (a) how smokeless tobacco use affects smoking behaviors and (b) how exposure to 
smokeless tobacco advertising affects use. Tomar reported that smokers were more likely to quit 
smoking than become users of smokeless tobacco.10 More importantly, users of smokeless 
tobacco were significantly more likely than nonusers of tobacco to become smokers.10 Some 
evidence indicates that smokeless tobacco marketing leads to greater use at least for adolescents.9 
Choi et al. found that exposure to advertising increased adolescents’ susceptibility to smokeless 
tobacco. One predictor of current use of smokeless tobacco is exposure to smokeless tobacco 
advertising, resulting in a sevenfold effect on current use.9  
Conclusions and Need for Future Research 
The body of evidence available to address the three concerns noted above is insufficient, 
and no previous systematic reviews have been done on these topics. We cannot draw any 
conclusions without studies on whether smokeless tobacco product marketing results in 
substituting smokeless tobacco for smoking or whether data on harm and harm reduction 
associated with smokeless tobacco are used to promote potential health effects of substituting 
smokeless tobacco for smoking. Consistent with one Surgeon General report,7 we consider 
smokeless tobacco users to be more likely to become smokers; this study we identified,10 
however, is insufficient to support definitive recommendations. Additionally, the body of 
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evidence is insufficient, given only one study,9 to determine conclusively whether tobacco 
marketing increases smokeless tobacco use or whether smokeless tobacco is a gateway drug for 
smoking. 
Topics in the area of smokeless tobacco product marketing that warrant future 
investigation are abundant. Several areas should be considered high priority for research: (1) 
whether new tobacco industry marketing strategies are increasing use of smokeless tobacco and, 
if so, whether the observed increase applies differentially to specific populations; (2) whether 
possible links between point-of-purchase tobacco promotion and advertising increase use of 
smokeless tobacco among adolescents and young adults; and (3) what strategies are effective to 
reduce use of smokeless tobacco among adolescents and young adults. Rigorous study designs 
(i.e., RCTs), longitudinal data, and longer follow-ups for cross-sectional data should be used to 
expand the smokeless tobacco product marketing and use evidence. Research has established 
links between use of smokeless tobacco and certain cancers;11 for that reason and the continuing 
development of effective smoking cessation treatment such as nicotine replacement therapy, 
future research should move away from investigating whether smokeless tobacco is a viable 
substitute for smoking and toward developing strategies to reduce its use. We see many 
opportunities in the area of smokeless tobacco research to build a stronger evidence base.  
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Genetics and Smoking 
Caryn Lerman, Ph.D. 
Despite progress made in the treatment of tobacco dependence, currently available 
treatments are effective for only a fraction of smokers. Although current guidelines recommend 
the use of nicotine patch as a first-line treatment for tobacco dependence, about 70–80% of 
smokers treated with the patch relapse to their former smoking practices in the long term. 
Bupropion has been shown to produce higher quit rates than nicotine replacement therapies 
(NRTs), yet the majority of smokers do not quit and remain abstinent. Thus, research is needed 
to identify subgroups of smokers for whom particular smoking cessation pharmacotherapies will 
have the strongest beneficial effects. These efforts may someday help practitioners to 
individualize smoking cessation treatment based on genotype, thereby maximizing its efficacy.  
Abundant data from animal model and human twin studies have established that smoking 
persistence is, in part, heritable.1 The emerging field of pharmacogenetics has the potential to 
advance the science of nicotine dependence treatment by generating new knowledge about 
genetic factors that influence the efficacy of different pharmacotherapies for smoking cessation.2 
The basic premise of this approach is that inherited differences in drug metabolism and drug 
targets have important effects on treatment toxicity and efficacy.3 This presentation provides a 
brief overview of evidence supporting the potential utility of a pharmacogenetic approach to 
smoking cessation treatment.  
Nicotine is metabolized to cotinine, and then to 3’-hydroxcotinine (3-HC), predominantly 
by the liver enzyme CYP2A6. Genetic variation in CYP2A6 predicts cigarette consumption and 
smoking persistence, consistent with the premise that faster inactivation and elimination of 
nicotine requires higher levels of smoking to maintain the desired levels of nicotine in the body.4 
The 3-HC:cotinine ratio derived from cigarette smoking (a phenotypic measure of CYP2A6 
activity) predicts the effectiveness of transdermal nicotine at the end of treatment and at 6-month 
followup. In a recent trial, the likelihood of abstinence was reduced by almost 30% with each 
increasing quartile of metabolic ratio (i.e., faster metabolism of nicotine).5  
With regard to genetic variation in drug targets, nicotine stimulates release of dopamine 
from neurons in the ventral tegmental area, an action thought to underlie its rewarding effects. 
Therefore, investigations have examined response to these alternate forms of NRT in relation to 
genetic variation in the dopamine pathway. Results of a large pharmacogenetic trial in the United 
Kingdom revealed greater efficacy of the nicotine patch (vs. placebo) among smokers with 
dopamine D2 receptor (DRD2) Taq1A genotypes associated with lower receptor density.6 
Likewise, a recent open-label NRT trial reported that smokers with a DRD2 polymorphism 
associated with lower transcriptional efficiency have significantly higher quit rates with the 
nicotine patch and nicotine nasal spray.7 Studies have also examined the role of the Catechol-O-
Methyltransferase (COMT) Val/Met functional polymorphism in response to NRT, as COMT is 
the primary enzyme involved in the degradation and inactivation of dopamine. Female smokers 
with the Met/Met genotype have a significantly higher probability of abstinence with either 
nicotine nasal spray or nicotine patch.8  
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Other pharmacogenetic analyses of NRT have focused on the role of the functional 
A118G variant in the mu-opioid receptor (OPRM1) gene. The mu-opioid receptor is the primary 
site of action for the rewarding effects of the endogenous opioid peptide, beta-endorphin, that is 
released following acute and short-term nicotine administration. Smokers carrying the low 
activity OPRM1 Asp40 variant are significantly more likely than those homozygous for the 
Asn40 variant to be abstinent following nicotine patch treatment (quit rates of 52% vs. 33% for 
Asp40 and Asn40 groups, respectively, odds ratio [OR]=2.4).9  
Pharmacogenetic analyses from bupropion trials have focused on drug metabolizing 
enzymes as well as polymorphisms in genes in the dopamine pathway. An initial report focused 
on the CYP2B6 gene, which has been implicated in bupropion kinetics, as well as in brain 
metabolism of nicotine. In this placebo-controlled randomized trial, smokers with a decreased 
activity variant of CYP2B6 (slower metabolizers) reported greater increases in cravings for 
cigarettes following the target quit date and had significantly higher relapse rates.10 These effects 
were modified by a significant gender × genotype × treatment interaction, suggesting increased 
efficacy of bupropion among female smokers with a genetic liability to relapse.  
Genetic variation in the dopamine pathway is also a plausible target for pharmacogenetic 
studies of response to bupropion treatment, since inhibition of dopamine reuptake is one putative 
mechanism for the beneficial effects of bupropion. Two pharmacogenetic trials suggest that 
smokers with the A2 allele (normal receptor density) for the DRD2 gene (Taq1A variant) may 
have a better response to bupropion.11,12 Further, a third trial reported an interaction between 
DRD2–141C Ins/Del genotype and bupropion treatment indicating a more favorable response to 
bupropion among smokers with genotypes associated with increased transcriptional efficiency.7 
Studies in this area suggest that smokers with genotypes associated with greater receptor density 
may have more D2 receptors available to bind dopamine, yielding a more rewarding experience 
of the nicotine-induced dopamine release. Blockade of dopamine reuptake by bupropion may be 
more effective in promoting abstinence in these genotype subgroups due to greater ability to bind 
dopamine.  
Pharmacogenetics research on nicotine dependence treatment is in the very early stages. 
To date, only two pharmacogenetic trials of NRT and three pharmacogenetic trials of bupropion 
have been conducted. Although the results of these initial studies are promising, there are several 
stages of research needed prior to translation to clinical practice. First, initial results from these 
trials must be validated in independent investigations. Large-scale pharmacogenetic trials (e.g., 
5,000 participants) are necessary to provide adequate power to conduct analysis of multiple 
genetic effects on treatment response simultaneously and to stratify for ethnic variation. 
Additional research should be conducted to examine the benefits, risks, and challenges of 
conveying genetic information about smoking predisposition to the patient, clinicians, and the 
public. Economic analyses of the cost-effectiveness of using genotype to tailor smoking 
treatment are also necessary. Clinical and ethical issues arising from the clinical use of genotype 
data in the smoking context must also be addressed, as many of the genetic variants that predict 
response to medications for smoking cessation may also portend an increased susceptibility to 
other drug addictions and psychiatric comorbidities. If these issues are addressed in parallel with 
the scientific research in pharmacogenetics, this work has the potential to improve public health 
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Treatment and Prevention of Tobacco Dependence  
in Individuals With Mental Health and Substance  
Abuse Disorders 
Sharon M. Hall, Ph.D. 
Epidemiological studies have shown that 41% of individuals with current Axis I mental 
disorders smoke cigarettes. In the United States, 44.3% of cigarettes consumed are smoked by 
people with Axis I Psychiatric Disorders.1 Individuals with Axis I and II disorders are also more 
likely to be nicotine dependent when compared to the general population.2  
Treatment 
This disproportionate representation extends to individuals in treatment for mental health 
and substance abuse disorders. Multiple studies show extremely high rates of smoking among 
drug treatment patients, ranging from 74% to 88%.3 Rates among individuals engaged in mental 
health treatment vary depending on disorder, but are higher than in the general population.4–7 
Given this overrepresentation of smokers among those with psychiatric illnesses, it is 
lamentable that the treatment of nicotine dependence in both substance-abusing and psychiatric 
populations is in its infancy, and the research is sparse.8 This is especially acute in psychiatric 
settings.9 There are multiple reasons for both the failure to offer treatment and the related lack of 
outcome data. In the substance abuse field, barriers includes staff resistance, lack of training,10,11 
and concerns about immediate critical needs such as housing and safety. Also, historically, there 
has been a belief in the substance abuse community that the preeminent task during recovery is 
abstinence from nonnicotinic drugs or alcohol, and that other health-related tasks should be 
delayed until that task is achieved.12 Finally, many drug treatment programs are poorly funded, 
and treatment of tobacco dependence has not been included in their mandate.9  
Some of the same barriers exist in mental health settings, including lack of training of 
providers, concern that other immediate needs take precedence, and reimbursement issues. In 
addition, there is concern that smoking cessation may cause a re-occurrence of the psychiatric 
disorder.13 Another important factor may be the relatively low status of tobacco dependence 
treatment among mental health policymakers and providers.8,9,14  
Despite the barriers to completing treatment studies and the paucity of treatment outcome 
data on the treatment of tobacco dependence in substance abuse settings, those available are 
promising. A recent meta-analysis has indicated that not only is smoking cessation effective in 
the treatment of tobacco dependence, but there also is no evidence that it increases relapse to 
other addictions. In fact, this meta-analysis hints that there is suggestive evidence that abstinence 
from tobacco is related to abstinence from other drugs.15 At least one well-done clinical trial has 
suggested that timing of the intervention may be important, however, and that, although patients 
are more likely to accept smoking treatment early in treatment for alcohol, they may be less 
successful in their abstinence from alcohol if they participate in early treatment.16 
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Data on the treatment of tobacco dependence in substance abuse treatment are sparse—
even more so in the treatment of tobacco dependence in mental disorders. The few clinical trials 
that exist suggest that interventions used in the treatment of the general population are effective 
with populations with mental disorders.17–19 Further, there is evidence that these interventions are 
especially effective if integrated into mental health services, as opposed to provided 
independently.17 Frequently, absolute abstinence rates have been lower than those observed in 
the general population,17,19 but this is not always the case.18 It seems quite reasonable that 
differences may be found as a function of the mental health disorder studied. Finally, despite 
concern about the recurrence of psychiatric disorders, especially Major Depressive Disorder, 
during and after smoking cessation and multiple case studies, the two large-scale studies of the 
issue produced conflicting results.20,21  
Prevention 
So far as we could find in preparing this abstract, there have been no studies of primary 
prevention for tobacco dependence for individuals with substance abuse or mental health 
disorders. In part, this may stem from the fact that many of these disorders develop concurrently 
with tobacco dependence or after the first use of nicotine. This is not the case with at least one 
disorder where high rates of cigarette smoking have been reported: Attention Deficit-
Hyperactivity Disorder (ADHD).22 Nevertheless, so far as we could find, no prevention studies 
with this subpopulation have been reported.  
Research on smoking cessation in the treatment of substance-abusing individuals and 
individuals with mental health disorders is very much in its infancy. Core questions, such as 
whether the interventions used in the general population perform in a similar fashion in these 
populations, have yet to be answered. Questions of timing, tailoring of the intervention to the 
specific problems of mental health and substance abuse patients, and the possible effects of 
cessation on mental health problems need study. Research on targeted prevention efforts is 
lacking. 
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Chronic Disease and Co-Occurring Risk 
Ellen R. Gritz, Ph.D. 
For many years, smoking cessation efforts have been aimed primarily at healthy persons 
in the general population, as a form of primary prevention. Individuals at elevated risk for certain 
diseases, or who had already experienced an illness—for example, cardiovascular disease (CVD) 
or early chronic obstructive pulmonary disease (COPD)—were targeted as well. However, 
smoking and tobacco cessation among persons with other types of severe chronic illness has 
received less attention from healthcare practitioners and researchers. This lack of emphasis may 
be attributable to the focus on acute treatment of a life-threatening illness, a potential or actual 
high mortality rate, lack of cessation treatment tailored to these populations, and the perceived 
lack of relevance of smoking to treatment outcome and survival. Two major examples are cancer 
and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), both of 
which have seen increased survival over the last decade.  
This presentation will focus on: (1) a brief overview of the evidence linking continued 
smoking to treatment complications, disease progression and adverse outcomes, including 
reduced survival in major smoking-related diseases including CVD and COPD, and the benefits 
of cessation; (2) other conditions in which smoking has a serious adverse impact—pregnancy, 
diabetes, and asthma; (3) evidence linking smoking behavior with increased complications and 
adverse outcomes for cancer and HIV/AIDS; and (4) the interest in quitting and motivation of 
persons with these two latter diseases to stop smoking. Best practices for healthcare providers 
treating such patients will also be reviewed. 
Cardiovascular Disease 
Cardiovascular disease encompasses a number of diseases, including coronary heart 
disease (CHD)—the leading cause of myocardial infarctions (MI)—cerebrovascular disease 
(stroke), aortic aneurysm, and peripheral vascular disease (PVD). Burns1 reviews a body of 
evidence relating to continued adverse effects of smoking after the onset of documented disease 
and concludes that, overall, continued smoking results in disease progression, recurrent events, 
and higher mortality, while smoking cessation reduces disease risks over time, depending on the 
specific condition. Smoking cessation after MI or angiographically documented coronary artery 
disease leads to significantly lower rates of re-infarction within 1 year, compared to continuing 
smokers; rates remain much lower over time. Among those with CHD, continued smoking was 
associated with an increased risk for sudden coronary death. Following coronary artery bypass 
surgery, continued smoking at 5 years is associated with increased risk for MI, angioplasty, and 
development of angina. Cessation of smoking following bypass surgery resulted in a 10-year 
survival of 84% versus 68% among continuing smokers.2 In patients with PVD, continued 
smoking is associated with much lower rates of improvement with medical management alone 
compared to nonsmoking patients, higher rates of amputation compared to quitters, and higher 
rates of obstruction following surgery.1 The Cochrane Collaboration meta-analysis (20 studies) 
estimated the magnitude of risk reduction when a patient with CHD stops smoking; it reported a 
pooled crude relative risk (RR) of 0.64 (0.58–0.71), representing a 36% reduction in all-cause 
mortality in ex-smokers compared to continuing smokers.3  
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Chronic Obstructive Pulmonary Disease 
COPD describes a range of conditions involving damage to the lungs, which arises 
primarily from the inhalation of tobacco smoke: chronic obstructive bronchitis, emphysema, and 
chronic airflow obstruction. Permanent cessation of smoking by individuals with early COPD 
(mild to moderate airway obstruction) dramatically reduces the progression to clinically serious 
lung disease as found in the Lung Health Study.4 Intervening once lung disease has become 
disabling results in a slowing in the rate of decline of lung function, but the benefits are more 
limited in terms of symptomatology.5 Mortality risk from COPD declines following smoking 
cessation compared to continued smoking, but this decline is smaller than for heart disease and 
lung cancer, and risk remains elevated in former smokers even after 20 years of abstinence.5  
Diabetes 
Both cross-sectional and prospective studies have consistently shown higher risk for 
micro- and macrovascular disease, as well as premature mortality in diabetic patients who 
smoke.6 Among adults with diabetes, smoking is associated with increased death by CHD, 
diagnosis of coronary artery disease, stroke, nephropathy, and neuropathy. Damage and 
constriction of blood vessels by smoking can lead to exacerbation of foot ulceration, blood vessel 
disease, and lower extremity amputation.7 The increased cardiovascular burden of diabetes 
among patients who smoke needs to be emphasized by healthcare providers; advice to quit is 
delivered to only about half of the smokers with diabetes.6,8,9 Special challenges involve smoking 
initiation by adolescent diabetics and, among smoking adults, problems of weight management, 
negative affect and interventions during hospitalization.6 
Asthma 
Maternal smoking during pregnancy and secondhand smoke exposure during childhood 
are associated with the onset of asthma and, in the latter case, its severity (as measured by 
frequency of attacks, number of emergency room visits, and risk of intubation).10–12 Reduction 
or, preferably, elimination of exposure to smoke in the home must be a major objective in the 
care of asthmatic children.13–17 
Reproductive Outcomes 
The risks of smoking on fertility and during pregnancy are well known and documented; 
these include reduced fertility, spontaneous abortion, premature delivery and low birth weight, 
and increased fetal and infant mortality.18 Research suggests that 17 to 25% of low birth weight 
births could be prevented by eliminating smoking during pregnancy.18,19 
Cancer20 
Tobacco use, including exposure to secondhand smoke, has been implicated as a causal 
or contributory agent in an ever-expanding list of cancers, including lung, head and neck, 
pancreas, liver, kidney, ureter, urinary bladder, uterine cervix, and myeloid leukemia. 
Independent of the etiologic effects of tobacco carcinogens in numerous cancers, a growing 
literature also documents the direct and indirect adverse effects of smoking on oncologic 
treatment efficacy (short- and long-term outcomes), toxicity and morbidity, quality of life 
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(QOL), recurrence, second primary tumors (SPT), and survival time. Despite the critical 
relevance of smoking to cancer outcomes, most oncology clinical trials do not collect data on 
smoking history and status unless the malignancy is widely acknowledged as smoking-related. 
Smoking history and status should be systematically collected as core data in all oncology 
clinical trials, from diagnosis and registration, throughout treatment and followup, to long-term 
survival or death. A set of items that are also useful in clinical practice is suggested for inclusion 
in clinical trial data sets. A much greater emphasis on smoking cessation for oncology patients is 
called for, and a treatment intervention literature is growing steadily.21–23 
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome 
(HIV/AIDS) 
Highly active antiretroviral therapy (HAART) has resulted in a dramatic decrease in 
AIDS-related mortality. Given the current trends in incidence and mortality, the number of 
people living with HIV/AIDS will continue to grow. The prevalence of smoking in HIV/AIDS 
populations is far above the national average (50–70% vs. 21%).24,25 HIV/AIDS patients who 
smoke are at elevated risk for numerous adverse outcomes (e.g., elevated mortality, 
cardiovascular disease, pulmonary infections, cancers, oral conditions and decreased QOL) 
compared to HIV-positive non-smokers.26,27 HIV-associated malignancies, such as anal and 
cervical cancer, are also observed more frequently among patients with HIV/AIDS who smoke. 
Risk factors for CVD are adverse side effects of prolonged antiretroviral therapy,28 and the 
number of CVD cases observed in this patient population has been growing in recent years.29 
Thus, it is vital that other major risk factors for CVD, particularly behavioral modifiable risk 
factors such as smoking, be targeted for intervention. To date, few efforts have been made to 
target HIV/AIDS patients for smoking cessation. A randomized controlled trial of a smoking 
cessation intervention tailored to a low-income, multiethnic population of individuals living with 
HIV/AIDS will be described.24,30,31 
Smoking Cessation Treatment for Persons Living with Chronic Disease 
In the past, fatalistic assumptions about cancer and HIV/AIDS outcomes may have led 
both patients and providers to underemphasize the benefits of smoking cessation. However, 
several studies have documented interest in and motivation to quit despite disease- and 
treatment-related barriers and other psychosocial/socioeconomic disadvantages.21,24,25,30–33 
Guidelines for treating smoking in persons with chronic disease, including the need for specific 
targeting and tailoring, and the use of appropriate pharmacotherapy, will be discussed.  
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Evidence-Based Practice Center Presentation:  
Effective Tobacco Cessation Strategies for Individuals  
With Co-Occurring Morbidities and Risk Behaviors 
Leah M. Ranney, Ph.D., M.A. 
Background 
Nicotine dependence among persons with co-occurring morbidities and risk behaviors 
occurs at an alarming rate.1,2 We define a person with co-occurring disorders as one who has a 
psychiatric condition and a nicotine addiction. Psychiatric conditions include schizophrenia, 
depression, anxiety, personality disorders, post-traumatic stress disorder, attention deficit 
disorder, eating disorders, and disruptive behavioral disorders. Risk behaviors trigger or 
exacerbate tobacco use such as alcohol and other chemical dependencies. 
Individuals with psychiatric conditions and nicotine addiction are twice as likely to 
smoke as the general population and to smoke more heavily than other smokers.1 As many as 
30% of smokers seeking cessation treatment have a history of depression.3 Smoking rates for 
alcohol and drug users are well above the average population, exceeding 70%. The risk of death 
is significantly higher for individuals with concurrent addictions of alcohol and nicotine than for 
individuals who abuse only alcohol or tobacco.3,4  
Using the analytic framework in figure 1, we undertook a systematic review of the 
evidence for effective smoking prevention and cessation treatments for people with co-occurring 
morbidities and risk behaviors (“key question 5” in the full evidence report).  
Figure 1. Cessation Strategies for Persons with Co-occurring Illness and Risk 
Behaviors: Analytic Framework 
 
Methods 
We searched standard electronic databases (MEDLINE®, the Cumulative Index to 
Nursing and Applied Health [CINAHL], Cochrane Collaboration libraries, Cochrane Clinical 
Trials Register, Psychological Abstracts, and Sociological Abstracts) between January 1, 1980 
and June 10, 2005 using Medical Subject Headings as search terms when available or key words 
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when appropriate. We limited our review to (1) human studies conducted in developed countries 
and published in English; (2) studies with participants ages 13 and older, of both sexes, and 
diverse racial and ethnic populations; (3) randomized controlled trials (RCTs) with 30 or more 
individuals; (4) observational studies and other trials with 100 or more individuals; and 
(5) studies with a minimum follow-up period of 6 months, with or without comparison groups. 
We excluded editorials, letters, and commentaries; articles that did not report outcomes related to 
our key questions; and studies that did not provide sufficient information to be abstracted.   
We reviewed all eligible studies, entered relevant data into evidence tables, and 
summarized them by descriptive methods. From our review of 639 abstracts, four addressed 
smoking cessation interventions for people with co-occurring morbidities and risk behaviors. We 
found no studies on prevention as a comorbid population by definition is already smoking. 
Results: Psychiatric Populations 
Approaches to increase quit rates among persons with psychiatric conditions include 
medications, educational strategies, and cognitive behavior modification.1 Although psychiatric 
populations had lower smoking cessation rates than nonpsychiatric populations, in the absence of 
relevant RCTs on smoking cessation for populations with psychiatric comorbidities, experts 
agree that clinicians should use smoking cessation treatments recommended for the general 
population such as pharmacotherapies and counseling.1,3 Prochaska et al. reported that 
multimodal strategies using nicotine replacement therapy in conjunction with psychosocial 
intervention strategies are effective in treating alcohol and other chemical substance users for 
tobacco addiction. Such interventions had positive short-term, but not long-term, effects.2 
However, smoking cessation interventions did not interfere with recovery from chemical 
dependency, a finding consistent with recommendations from other reviews.2,3  
Among the four studies that addressed smoking cessation for people with co-occurring 
morbidities and risk behaviors, two evaluated smoking cessation for persons with psychiatric 
conditions. Hitsman et al. hypothesized that smokers with greater depressive symptoms would be 
more likely to achieve abstinence when receiving fluoxetine combined with cognitive behavioral 
therapy (CBT) than when receiving a placebo and CBT.5 Participants treated with fluoxetine had 
a higher likelihood of abstinence as compared with participants treated with placebo. At 3 
months, fluoxetine benefited smokers with higher initial levels of depression. Conversely, 
placebo-treated participants with increasing depression scores were associated with decreasing 
likelihood of abstinence.5 Another trial focused on adolescent smokers ages 13–17 who had been 
hospitalized for psychiatric and substance use problems;6 neither motivational interviewing nor 
brief-advice tobacco cessation interventions was effective for this population. 
Smoking cessation is challenging in populations with psychiatric disorders.1 Evidence is 
insufficient and inconsistent about smoking cessation interventions in populations with 




Results: Alcohol and Substance Abuse 
Two studies investigated smoking cessation among alcohol and substance abusers.7,8 
Covey et al. examined the influence of a history of alcoholism or major depression on smoking 
cessation rates in a 10-week RCT of clonidine on smokers who received individual behavioral 
counseling, or a placebo for 10 weeks in place of clonidine.7 Rates of smoking cessation did not 
differ significantly between alcoholic and nonalcoholic participants. Male smokers who had both 
alcoholism and major depression demonstrated a severely impaired ability to stop smoking 
compared with those having alcoholism but not major depression. The results indicated 
equivalent smoking cessation rates for recovering alcoholics as compared with rates for the 
general population, but findings suggest smoking cessation strategies may need to be tailored for 
smokers with a history of alcoholism and diagnosis of depression. 
Joseph evaluated the feasibility of a smoke-free policy and a nicotine treatment program 
implemented in a drug and alcohol treatment hospital.8 At 1-year follow-up, the number of 
patients who quit was greater among those admitted to the hospital after the start of the smoke-
free and nicotine treatment policy than among patients admitted to the hospital before the policy 
changes. There was no effect on non-nicotine substance use.  
We could not determine the effectiveness of smoking cessation interventions in 
populations with alcohol or substance abuse addictions. Two studies reported significant effects 
for smoking cessation without affecting abstinence for other addictive substances,7,8 but 
abstinence was not maintained over time.7 The studies supported findings from past reviews 
about the positive short-term effects of such interventions;2 however, the body of evidence is 
insufficient to point to further recommendations. 
Conclusions and Need for Future Research 
How best to approach smoking cessation treatment in populations with co-occurring 
morbidity and risk behaviors is controversial; successfully accomplishing therapy may require 
tailored smoking cessation treatments.2,7 Comprehensive research on concurrent treatment for 
smoking cessation and chemical dependency is warranted in light of recent data indicating no 
adverse effects on sobriety or other drug use.2,8 Investigators need to explain the interaction 
between depression and impaired ability to stop smoking among people diagnosed with clinical 
depression and among alcoholics or people with a history of alcoholism. Because populations 
with these additional ailments and problem behaviors smoke at higher rates than others,1,2 special 
attention should be directed toward treating nicotine addiction concurrently with recovery and 
management of other medical issues. Finally, barriers to smoking cessation treatment in patients 
with other health problems, such as contraindications of pharmacotherapy, and the validity of 
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